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The Role of HuR in Mediating Ovarian Cancer Treatment 
Yu-Hung Huang 
Abstract 
An mRNA-binding protein, HuR (Human antigen R, aka ELAVL1), is 
highly elevated in many cancers, and is a master regulator of gene expression. 
HuR-regulated genes are involved in cancer cell survival, growth, and metastasis. 
In ovarian cancer, cytoplasmic accumulation of HuR is associated with poor 
prognosis. High HuR expression in ovarian cancer cells provides a rationale for 
targeting HuR as a therapeutic strategy.   
 Here, we found that silencing HuR in ovarian cancer cells in culture 
by transient transfection of small interfering RNA (siHuR) or by stable 
expression of short hairpin RNA (shHuR) significantly decreased cell 
proliferation and anchorage-independent growth, and impaired migration and 
invasion. Furthermore, systemic administration of siHuR-conjugated folic acid 
(FA)--derivatized DNA dendrimer nanocarrier (3DNA®) to ovarian tumor-
bearing mice suppressed tumor growth and ascites development, and 
significantly prolonged lifespan. Using NanoString gene expression analysis, we 
showed that suppression of HuR disrupts multiple essential cellular molecular 
pathways needed by ovarian tumor cells to survive, a finding that sets this 
therapeutic approach apart from other therapies that target a single gene. 
These results are the first to demonstrate the versatility of the 3DNA 
                                                                                                                                                                                              
 
 
nanocarrier for in vivo targeted delivery of a cancer therapeutic, support the 
notion that HuR is a promising target, and support the potential use of FA-
derivatized 3DNA dendrimer for siHuR targeted delivery to ovarian tumor cells 
for treatment of advanced ovarian cancer patients.  
Given that HuR serves as a predictive marker for gemcitabine efficacy in 
pancreatic cancer, we performed a retrospective study of ovarian cancer patients 
aiming to investigate the role that HuR plays in the response of high-grade 
serous ovarian tumors to chemotherapeutics. We found that there is no 
correlation between HuR intracellular localization and progression free survival 
(PFS) following second-line therapy with gemcitabine, usually administered in 
combination with carboplatin. We further performed ribonucleoprotein 
immunoprecipitation (RNP-IP) on ovarian cancer cells in culture to determine if 
HuR regulates deoxycytidine kinase, a metabolic enzyme that activates 
gemcitabine. We also examined the effects of carboplatin treatment on 
expression of HuR and the mitotic inhibitor WEE1, and on cell cycle kinetics. 
Treatment of cells with gemcitabine upregulated deoxycytidine kinase (dCK), 
while treatment with carboplatin upregulated both HuR and WEE1 expression. 
One would expect enhancement of gemcitabine activation and efficacy resulting 
from elevated dCK to be impeded by elevated WEE1 expression. This may 
explain why HuR cytoplasmic localization is not predictive of therapeutic 
response to combination gemcitabine/carboplatin therapy and PFS. These results 
suggest combination treatment of recurrent ovarian tumors with gemcitabine, 
                                                                                                                                                                                              
 
 
carboplatin, and a WEE1 inhibitor may be potentially advantageous as 
compared to current clinical practices. 
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Chapter 1 
Ovarian cancer 
 
1.1 Classification 
Ovarian cancer is the most lethal gynecological cancer among women 
with estimated annual incidence of approximately 200,000 new cases and 
125,000 deaths worldwide [1]. The common classification system used to define 
the dissemination of ovarian cancer and metastasis is the International 
Federation of Gynecology and Obstetrics classification system (FIGO) [2].  It 
classifies ovarian cancer using a I to IV staging system (Table 1). In general, 
stage I ovarian tumors are confined to the ovaries, stage II tumors have grown 
outside of ovaries but are restricted to the pelvis, stage III tumors have spread 
outside the pelvis into the abdominal cavity, and stage IV tumors are present in 
body organs other than the ovaries, such as liver and lungs.  If ovarian cancer is 
only found on the surface of the liver and not within the liver itself, however, 
then the cancer is still classified as stage III. Furthermore, the microscopic 
appearance of tumor cells is used to grade ovarian cancer, (grade 1, 2, and 3), 
according to their differentiation state. If an ovarian tumor has the cellular 
morphology similar to healthy tissue, it is a differentiated tumor, and classified 
as a low-grade tumor. On the other hand, if the cancerous tissue has lost its 
cellular morphology and looks very different from healthy tissue, it is a poorly 
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differentiated or undifferentiated tumor, and classified as a high-grade tumor. 
The cancer grading system may help to predict how quickly the cancer will 
metastasize and a patient’s prognosis.  In general, patients with a lower-grade 
ovarian tumor have a better prognosis than those with higher-grade tumors. It is 
important to note that two ovarian tumors with the same grade classification 
may have different specific histologies.  
 
1.2 Risk factors 
              BRCA1 and BRCA2 mutations can dramatically increase risk of 
ovarian cancer[3]. The increased chance for a BRCA1/2 mutation carrier to 
develop ovarian cancer is ~15-60%, the range reflecting the risk associated with 
specific point mutations [3]. In women having a first-degree relative with history 
of breast cancer, ovarian cancer, or both, the likelihood of developing ovarian 
cancer is also increased [4]. Age is another important risk factor for 
development of ovarian cancer due to the increased risk of developing sporadic 
ovarian cancer associated genetic mutations, with a maximum incidence of 61.8 
mutations per 100,000 women in the 80–84-year age group [3]. Other possible 
risk factors for epithelial ovarian cancer lack direct evidence, and include 
infertility, endometriosis, post-menopausal hormone replacement therapy, pelvic 
inflammatory disease, polycystic ovaries, obesity and high caloric consumption 
[3, 5].  
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1.3 Screening 
Screening tests and exams are developed with the goal of detecting a 
person’s genetic predisposition for developing a disease prior to any symptoms, 
or for detecting a disease at a very early stage. Despite improvements in 
treatment, early detection still remains the most effective way to manage cancer. 
One of the best examples for early cancer detection is the mammogram which 
can often detect breast cancer in its earliest stage, even before the tumor 
becomes palpable. The chance of surviving ovarian cancer can dramatically 
increase if early stage disease can be detected. Unfortunately, due to the 
asymptomatic nature of this cancer and the lack of effective detection methods, 
most patients present with advanced ovarian cancer upon diagnosis. Despite a 
large effort to develop a screening test for ovarian cancer, there hasn’t been 
much success so far. Pelvic palpation, transvaginal ultrasound, and levels of 
the cancer antigen 125 (CA-125) in blood serum are currently used in clinic to 
screen for ovarian cancer [6].  
   The major drawback for transvaginal ultrasound is that it cannot 
distinguish benign cysts from malignant tumors. When it is used for screening, 
most of the masses found are not cancerous. The amount of CA-125 is often 
elevated in the serum of women with ovarian cancer, but not always. CA-125 
level can be used to monitor cancer treatment as its level decreases if the 
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treatment is working. However, for early detection of ovarian cancer, CA-125 is 
not an ideal biomarker, the major issues being a lack of sensitivity, particularly 
for detecting early stages of ovarian cancer, and its poor specificity, especially in 
premenopausal women [7].  Normal physiological conditions other than cancer 
can also increase CA-125 level (e.g., menstrual cycle), and not everyone who 
has ovarian cancer has a high CA-125 level. False positive results put patients 
through unnecessary medical tests and procedures while false negative results 
delay diagnosis and treatment. Thus, CA-125 test has not been recommended for 
screening ovarian cancer in asymptomatic women [8]. A study conducted to 
examine the screening accuracy of CA-125 combined with transvaginal 
ultrasound to detect ovarian cancer in 22,000 women found no advantage in 
overall survival [8]. However, a recent study showed that CA-125 level 
interpreted in combination with the risk of ovarian cancer algorithm (ROCA), a 
program that calculates a risk of having a change-point based on a woman’s age 
and CA-125 profile, could greatly improve screening sensitivity [9]. 
Unfortunately, the current screening method cannot distinguish different 
histologic types of ovarian tumors, and can only detect ~ 25% of low-grade 
ovarian cancers, which account for approximately 10% of ovarian cancer deaths 
[10]. Ineffective screening is the primary the reason why the overall survival for 
women with this disease has not changed over the last 50 years. The human 
epididymis protein 4 (HE4), one of the most frequently upregulated genes in 
ovarian carcinomas, has been proposed as a potential biomarker for ovarian 
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cancer [11-13]. HE4 as a biomarker in detecting ovarian cancer has been 
demonstrated more sensitive than CA-125 [14, 15] and received approval as an 
ovarian cancer recurrence monitoring marker by FDA. Moreover, the 
combination of HE4 and CA-125 achieved the highest sensitivity among other 
single markers or dual-marker combinations for ovarian cancer detection [16]. 
However, to attain the minimally tolerable positive predictive value of 10% for 
ovarian cancer detection at all stages, it requires a screening method with a 
sensitivity of 75% and a specificity of ~99.7% [16]. Improvement to 
detect/diagnose ovarian cancer is still greatly needed. Hopefully the 
development of new screening tests will eventually lead to a lower ovarian 
cancer death rate. 
 
      1.4 Ovarian cancer: Not a single disease 
Ovarian malignancies consist of Germ cell tumors, sex cord-stromal 
tumors, and surface epithelia tumors (carcinoma) [17]. Germ cell tumors 
account for ~5% of ovarian malignancies and develop from the ovum-producing 
cells in the ovaries [18]. Most germ cell tumors are benign; if cancerous, the 
most common malignancies are maturing teratomas, dysgerminomas, and 
endodermal sinus tumors [18]. Ninety percent of patients with ovarian germ cell 
malignancies can be successfully treated without affecting fertility. Ovarian 
stromal tumors are also a rare type of ovarian cancer, accounting for less than 
5% of cases [18]. They develop from connective tissue cells and the female 
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hormone producing cells, the most common types being granulosa-theca and 
Sertoli-Leydig cell tumors [18].  
Ovarian carcinoma accounts for over 90% of ovarian cancer cases [3]. 
Various histopathological morphologies and different genetic expression 
profiles make ovarian carcinoma extremely heterogeneous. Ovarian carcinoma 
can be classified by cellular histopathology into serous, mucinous, endometriod, 
clear cell, and transitional (Brenner) tumors with cellular morphologies 
corresponding to different types of epithelia in the female reproductive tract [19]. 
A dualistic model was proposed by Shih and Kurman group in 2004 with an 
intention to simplify categorization of various ovarian cancer histotypes [19]. 
The model is based on signaling pathway activation [20] and gene expression 
profiling [21], to divide different histosubtypes of ovarian carcinoma into two 
groups, Type I and Type II. Each group has its distinctive morphologic features 
and unique genetic signatures. In general, Type I tumors are low-grade, slow in 
growth, and usually confined to the ovaries upon diagnosis [22]. This type of 
ovarian carcinoma exhibits a shared lineage with the corresponding benign 
cystic neoplasm, often presenting with histopathology of an intermediate 
borderline tumors [22]. Although they are less responsive to chemotherapeutic 
drugs largely due to slow cell division, patients with type I tumors have better 
outcome than patients with high-grade tumors. Type I tumors include low-grade 
serous, low-grade endometrioid, clear cell, mucinous, and transitional (Brenner) 
tumors, and each histologic type exhibits a distinctive molecular genetic profile 
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[23].  Type I tumors are relatively genetically stable [22, 24, 25]. About two 
thirds of low-grade serous carcinomas carry KRAS, BRAF, and ERBB2 
mutations and mutations in the PI3K-Akt pathway (e.g., PTEN mutation and 
PI3K-CA amplification are common). TP53 mutations are rare in these tumors. 
Abnormalities in the Wnt signaling pathway is often detected in low-grade 
endometrioid carcinomas along with somatic mutations of CTNNB1 (encoding 
ß-catenin), PTEN, and PI3KCA [26]. KRAS is mutated in 50% of mucinous 
carcinoma specimens [27]. From analysis of tumor samples and cell lines, a high 
percentage of clear cell carcinomas have PI3KCA active mutants [28]. The 
molecular genetic feature of transitional cell (Brenner) tumors has recently 
analyzed with somatic mutations of CDKN2A, KRAS, and PI3KCA [29].   
In contrast, type II tumors include high-grade serous, high-grade 
endometrioid, and undifferentiated carcinoma (depending on the dominant 
pattern, designated type II). These tumors are highly aggressive with rapid 
evolvement, most commonly present at an advance staged in clinic, and patients 
have poor patient outcomes. [22, 24]. They account for approximately 75% of 
all ovarian epithelial carcinomas and are responsible for 90% of ovarian cancer 
deaths [10], which contributes to the erroneous perception that ovarian cancer is 
a single disease. Unlike the distinctive morphologies that characterize type I 
tumors, type II tumors display a large amount of morphologic and molecular 
heterogeneity, often exhibiting papillary, glandular, and solid phenotypic 
regions, and gene expression variability [30]. The molecular signature of type II 
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tumors is characterized by extremely frequent p53 mutations (over 80-95 % of 
cases) [22, 24, 31-34] and CCNE1 (encoding cyclin E1) amplification. However, 
these tumors rarely carry the genetic mutations found in type I tumors, such as 
KRAS, BRAF, ERBB2, PTEN, CTNNB1, and PI3KCA [22]. About 10% ovarian 
carcinomas are hereditary and most are related to BRCA mutations [35, 36]. 
Most of the BRCA-related hereditary ovarian tumors are high-grade serous 
carcinoma. BRCA1 and BRCA2 are enzymes in homologous recombination 
DNA repair pathways and appear to functions as tumor suppressors, similar to 
p53. Thus, women who have an inherited germline mutation of BRCA and 
subsequently gaining somatic loss of the other wild-type allele are at high risk to 
develop ovarian carcinoma [23]. The exact interaction between mutations of 
BRCA and TP53 in ovarian carcinoma is unclear. Interestingly, type II tumors 
respond favorably to chemotherapeutic drugs due to rapid cell division, but often 
these tumors develop resistance to the therapy following an initial response. The 
fact that each type of ovarian carcinoma exhibits unique morphologic and 
molecular features suggest that different types develop from genetic alterations 
in different pathways. The associated molecular genetic changes in different 
histologic types of ovarian cancer are summarized in Table 2 [29, 30]. 
 
1.5 Ovarian carcinoma: origin 
Despite the profound morphologic and molecular differences among 
histotypes, ovarian cancer has long been viewed as a single disease. The 
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determination of the origin of ovarian cancer can help to develop a proper 
diagnosis tool, and effective therapeutics. In a traditional view, ovarian 
carcinoma originates from the ovarian surface epithelium (mesothelium), then 
invaginates into the stroma forming so-called “cortical inclusion cysts”. Under 
the influence of hormones and other factors, these cysts subsequently undergo 
metaplastic changes (conversion of mesothelium to mullerian epithelium) 
leading to the development of the different cell types [serous, endometrioid, 
clear cell, mucinous, and transitional cell (Brenner)], which morphologically 
resemble epithelia of the fallopian tube, endometrium, gastrointestinal tract, or 
endocervix and urinary bladder, respectively. In this scheme, upon growth, 
ovarian cancer later spreads from the primary site (ovaries) to the pelvis, 
abdomen, and distant sites. However, there are problematic incongruities in 
assigning the origin of ovarian carcinoma to the ovarian surface epithelium. The 
simple epithelial cell layer of normal ovaries has no morphologic counterparts 
resembling the morphology of type I and II tumors. Interestingly, ovaries 
develop from mesodermal epithelium on the urogenital ridge, but the cervix, 
endometrium and fallopian tubes are derived from the mullerian ducts. Although 
mullerian types of epithelium are often detected in the ovarian cortex, a 
transition from cyst to carcinoma has not been reported. Moreover, inclusion 
cysts displaying morphology of intestinal epithelium that resembles mucinous 
carcinoma, and transitional type epithelium that resembles Brenner tumor, are 
very rare.  These limitations lead to an alternate theory that ovarian carcinoma 
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(serous, endometrioid, and clear cells) derive from mullerian tissue, not from 
mesothelium [37]. According to this theory, ovarian tumors develop from the 
paratubal and paraovarian mullerian tissue collectively referred to as the 
“secondary mullerian system” [38, 39]. As a tumor increases in size, it 
eventually compresses and outgrows ovarian tissue making the tumors seem to 
arise from ovaries.  The major drawback for this theory is that precursor lesions 
resembling serous, endometrioid, and clear cells carcinomas have rarely been 
reported in paratubal and paraovarian cyst.   
In 2001, a Dutch group reported that tumor precursor lesions found in 
the fallopian tubes of women at risk for developing ovarian cancer closely 
resembled high-grade ovarian serous carcinoma [40]. In addition, similar lesions 
have been reported in studies of normal appearing ovaries and in ovaries of 
women having a genetic predisposition to ovarian cancer.  Additional studies of 
fallopian tubes of women with a genetic prediposition to ovarian cancer detected 
early invasive tubal carcinomas [41-44]. This led to a proposal that some 
ovarian carcinoma resulting from inherited BRCA mutations might develop 
from the implantation of malignant cells of tubal carcinoma to the ovary [45, 46]. 
Moreover, over 70% sporadic (non-hereditary) ovarian high-grade serous 
carcinomas have mucosal tubal involvement including “serous tubal 
intraepithelial carcinoma” (STICs) [47]. Further studies showed that nearly all 
STICs overexpress p53 (similar to high-grade serous carcinoma)  and also share 
morphologic features and harbor mutated TP53 identical to high-grade serous 
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carcinoma, the observations that support a clonal relationship between STICs 
and ovarian tumors [47]. A gene profiling study revealed that the gene 
expression profile of high-grade serous carcinoma is more closely related to the 
fallopian tube than to the ovarian surface epithelium [48].  Strikingly, high-grade 
serous carcinomas express a mullerian marker, PAX8, whereas a mesothelial 
marker, calretinin, is absent [22]. This observation led to a proposal that STICs 
are likely to be the source of ovarian high-grade serous carcinoma both in 
women with BRCA mutations as well as in those women without a known 
genetic predisposition to ovarian cancer.  
In the case of low-grade serous carcinomas, the tumorigenic process is 
slow, presenting in a stepwise manner [19, 23]. It starts from direct implantation 
of fallopian tube epithelial cells from fimbria into ovum during ovulation where 
the surface epithelium is disrupted. The implants later form an inclusion cyst. 
After attaining KRAS or BRAF mutation, the implants develop a serous 
cystadenoma and then a serous borderline tumor, subsequently low-grade serous 
carcinoma. Occasionally, low-grade serous carcinoma can advance to high-
grade if a TP53 mutation occurs. It is now clear from results of morphologic and 
molecular genetic studies that low-grade endometrioid and clear cell carcinomas 
develop from endometriotic cysts (endometriomas) that are associated with 
implants of endometrium in the pelvis [49].  
The origin of mucinous and transitional (Brenner) tumors still remains 
unknown. From morphologic comparison, they do not display a mullerian 
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phenotype (e.g., serous, endometrioid, and clear cell tumors) or a mesothelium 
phenotype (ovarian surface epithelium). Instead, they bear close resemblance to 
gastrointestinal mucosa (mucinous tumors) and urothelium (Brenner tumors). 
Furthermore, cortical inclusion cysts displaying mucinous and Brenner 
morphologic features are very rare. A proposed concept that mucinous and 
Brenner tumors develop from the same origin began with the observation of 
mucinous cystadenomas contained foci of Brenner tumor in 18% of cases [50]. 
This observation provides a possibility that mucinous and Brenner tumors might 
have the same histogenesis developing from transitional cell nests at the tubal-
mesothelial junction leading to development of their nonmullerian morphology. 
It is suggested that as a tumor grows from the tubal-mesothelial junction, the 
dominant phenotype changes from Brenner to mucinous. As the tumor continues 
to grow, it eventually compresses and obliterates the adjacent ovary making the 
tumor appear to develop from ovary. The proposal is still lacking strong 
evidence and requires further validation.   
Together, all of the proposed theories of ovarian histogenesis offer 
inconclusive explanations for the development of ovarian carcinomas, but 
require additional morphologic and molecular genetic studies to determine 
whether these concepts are valid. They do, however, strongly indicate that what 
was thought to be the primary epithelial ovarian carcinoma, is in fact, secondary. 
Further study of this new paradigm for the origin of ovarian cancer will allow 
scientists to develop more rationale approaches to screening, treatment, and 
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prevention of ovarian cancer, and hopefully can make a significant impact on 
the overall survival for the patients.  
        
      1.6 Ovarian cancer: management 
Current therapies for ovarian cancer are based on tumor stage and 
grade, rather than on the histological type [51]. The standard treatment for 
patients with advanced stage ovarian cancer of all histological types is optimal 
surgical debulking followed by combination chemotherapy. For patients with 
advanced ovarian cancer, surgery involves a total abdominal hysterectomy, 
bilateral salpingo-oophorectomy and infracolic omentectomy and, if necessary, 
lymphadenectomy. Optimal cytoreductive surgery has long been shown to 
improve survival for patients with advanced ovarian cancer [52]. Platinum-based 
chemotherapy drugs (cisplatin and carboplatin) became the first-line 
chemotherapy for patients with advanced ovarian cancer after 45 randomized 
trials involving nearly 10,000 patients showed an overall survival advantage at 
both 2 and 5 years [53].  Paclitaxel was shown to improve survival advantage 
when combined with cisplatin and became one of the first-line 
chemotherapeutics [54]. Subsequently, carboplatin was shown to be less toxic 
than cisplatin and became the drug of choice to combine with paclitaxel as the 
standard first-line chemotherapy for women with advanced ovarian cancer [55]. 
Hormone therapy uses hormones (tamoxifen) or hormone-blocking drugs 
(Aromatase inhibitors) to treat cancer and is rarely used to treat epithelial 
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ovarian cancer, but is used more often to treat ovarian stromal tumors.  Drugs 
that have been shown to have activity in treating patients with recurrent 
platinum-resistant ovarian cancer are listed in Table 3 [56]. 
The complexity of ovarian cancer, including the asymptomatic nature 
of early disease and diverse histosubtypes with unique molecular signatures, 
makes effective treatment difficult. The fact that the mortality rate of ovarian 
cancer has remained unchanged for several decades despite advances in 
combination therapies attests to our poor management of this disease. The 
overall 5-year survival rate is only 46%. This is largely because, in current 
clinical practice, ovarian cancer is regarded as a single disease regardless of new 
knowledge defining genetic and histological differences among tumor types. 
The development of drug resistance by tumor cells is another major factor that 
negatively impacts patient survival. The need for alternative therapies is great.  
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       Table 1. FIGO Classifications for Ovarian Cancer 
Stage FIGO Classifications for Ovarian Cancer 
I Tumor confined to the ovaries 
IA 
Tumor confined to one ovary (capsule intact); no tumor on ovarian surface; no 
malignant cells in peritoneal washings 
IB 
Tumor confined to both ovaries (capsules intact); no tumor on ovarian surface; 
no malignant cells in peritoneal washings 
IC 
Tumor confined to one or both ovaries (capsule ruptured), tumor on ovarian 
surface, malignant cells in peritoneal washings 
II Tumor involves one or both ovaries and pelvic  
IIA 
Tumor implants found on the uterus and/or fallopian tube(s); no malignant cells 
in peritoneal washings 
IIB 
Tumor implants found in other pelvic tissues; no malignant cells in peritoneal 
washings 
IIC 
Tumor implants found in other pelvic tissues with malignant cells in peritoneal 
washings 
III 
Tumor involves one or both ovaries with peritoneal metastasis outside the 
pelvis 
IIIA Microscopic peritoneal metastasis outside the pelvis (no macroscopic tumor) 
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IIIB 
Macroscopic peritoneal metastasis outside the pelvis 2 cm or less in greatest 
dimension 
IIIC 
Macroscopic peritoneal metastasis outside the pelvis >2 cm in greatest 
dimension and/or regional lymph node metastasis 
IIIC Metastasis found in regional lymph nodes  
IV Metastasis detected in distant organs 
        
       Source: Int J Gynaecol Obstet. 2014 Jan. 124 (1):1-5 
 
 
 
Table 2. Frequent molecular genetic changes in epithelial ovarian cancer (EOC) 
 
 Type I EOC Type II EOC 
Histostypes High-grade serous Low-
grade 
serous 
Endometrioid Mucinous Clear 
cell 
Brenner 
tumor 
Associated 
molecular 
genetic 
changes 
TP53 mutation, 
Inactivation of 
BRCA 1 and 2, 
Chromosomal 
instability 
KRAS 
BRAF 
ERBB2 
PIK3CA 
 
ARID1A 
CTNNB1 
PTEN 
PIK3CA 
PPP2R1A 
 
KRAS  ARID1A 
PIK3CA 
ZNF217 
PPP2R1A 
 
CDKN2A 
PIK3CA 
KRAS 
Source: Hum Pathol. 2011 July; 42(7): 918–931.; Mod Pathol. 2014 February; 27(2): 231–237 
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Table 3. Chemotherapeutics for treatment of patients with recurrent platinum-
resistant ovarian cancer. 
Chemotherapeutics 
Topotecan 
Paclitaxel 
Docetaxel 
Liposomal Doxorubicin 
Etoposide 
Gemcitabine 
Oxaliplatin 
Hexamethylmelamine 
Ifosfamide 
Vinorelbine 
Tamoxifen 
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Source: Annals of Oncology 17 (Supplement 5): v188–v194, 2006 
 
 
 
 
 
 
Chapter 2 
HuR biology 
 
2.1 Overview: post-transcriptional gene regulation 
                 As proposed by Hanahan and Weinberg, normal cells that become 
cancerous need to acquire specific capabilities including enhanced proliferation 
resulting from sustained proliferative signaling, a continuum of cell growth-and-
division cycles, enabling replicative immortality, survival from apoptotic 
stimulation, immune evasion, angiogenesis development, and invasion and 
metastasis [57]. To achieve these specific functions, cancer cells require distinct 
protein expression profiles through activation of many cellular processes. In 
ovarian cancer, genetic mutations (e.g., KRAS, BRAF, ERBB2, and TP53) 
[30]and modified transcription (e.g., overexpression of EpCAM resulting from 
DNA methylation and histone modifications) [58] transform normal cells to a 
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cancerous state and provide cells with a unique gene expression profile to ensure 
survival advantage. These processes often take a long time to evolve and 
achieve biologic influence. On the other hand, to survive in the local volatile 
microenvironment, cancer cells, instead, adopt exquisite post-transcriptional 
regulation to modify gene expression quickly. The post-transcriptional gene 
regulation, the process that controls gene expression at the RNA level, can 
rapidly and efficiently change gene expression profile in contrast to alterations 
at the DNA level.  Unlike genetic modifications, post-transcriptional gene 
regulation is also a powerful mechanism by which cells can respond rapidly and 
efficiently to the environmental changes (e.g., hypoxia), by effecting changes in 
multiple signaling pathways at once. Subsequently, global changes in the 
proteome can dramatically alter cellular phenotype during the normal processes 
of development and differentiation, and promote the survival of cancer cells [59-
66].  
                Post-transcriptional gene regulation is controlled by a series of 
processes that includes alternative splicing, RNA modification (e.g. conversion 
of adenosine to inosine), polyadenylation, messenger RNA (mRNA) 
transportation and localization, mRNA translation, and mRNA turnover 
(stabilization and decay) [67].  Regulation of these cellular processes is 
governed mainly by RNA-binding proteins (RBPs), and trans-acting micro 
RNAs (miRNAs) (examples of RBPs and microRNAs involved in each process, 
see Table 1) [68-70]. The tricky balance between miRNAs, RBPs, and their 
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target RNA transcripts needs to be craftily maintained in cells to ensure all 
aspects of cell biology functioning properly [71]. For example, miRNAs 
associate with RBPs to form microRNPs (miRNP) which regulate RNA stability 
and translation by binding to complementary sequences in target mRNAs. A 
distortion of the balance, even by aberrant expression of a single miRNA or a 
RBP can lead to initiation and/or progression of many diseases, including cancer.  
                In cancer cells, specific RBPs tightly control post-transcriptional 
processes of a great number of oncoproteins and tumor suppressors, often in a 
tissue-specific manner [68]. Among elevated proteins in ovarian cancer, the 
RNA binding protein HuR/ELAV1 (embryonic lethal abnormal vision 1) has 
been identified as one that is highly overexpressed and its overexpression 
correlates with cancer progression. Besides RBPs, miRNAs provide an 
additional layer of gen regulation. Some miRNAs have been shown to be up-
regulated, while others are down-regulated in many human cancers; they can 
function as oncogenes by down-regulating tumor suppressor genes, and act as 
suppressor genes by negatively regulating genes that promote tumor growth and 
progression [72]. MiR-221 and miR-222 are well known miRNAs that function 
as oncogenes by targeting and inhibiting the expression of the tumor suppressor 
gene, p27Kip [73]. Using a miRNA microarray to analyze and compare the 
miRNA expression profiles of 20 serous ovarian carcinomas and comparing 
them with normal ovarian samples, Nam et al. found upregulated miRNAs 
(miR-16, miR-20a, miR-21, miR-23a, miR-23b, miR-27a, miR- 93, miR-141, 
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miR-200a, miR-200b, and miR-200c) and downregulated (miR-10b, miR-26a, 
miR-29a, miR-99a, miR-100, miR-125a, miR-125b, miR-143, miR-145, miR-
199a, miR-214, and let-7b) [74]. The striking discovery has also been made that 
miRNA signatures differ among ovarian carcinoma histotypes (serous, 
endometrioid, clear cell, and mucinous) [75]. 
 
2.2 RNA-binding proteins, Hu/ELAV family  
                 RNA-binding proteins (RBPs) are master regulators of mRNA 
processing and translation, and their expressions are often aberrant in cancer 
cells [76]. In addition to cancer-associated transcription factors, RBPs are 
emerging as important players in tumor development and progression [76]. 
RBPs, along with noncoding RNAs (particularly miRNAs) and their mRNA 
targets, form a complex network that plays a crucial role in maintaining cellular 
homeostasis. Many RBPs are aberrantly expressed in cancer cells and thus have 
thus a cancer-specific regulatory activity. Acquisition of cancer-specific traits 
has been directly linked to the function of RBPs [77, 78]. RBPs recognize 
specific sequences and/or secondary structures that typically reside in the 
untranslated regions (UTRs), often at the 3’-end, but also in the 5’UTR and the 
open reading frame (ORF) of target mRNAs [79]. 
                Among RBPs, the Hu/ELAV (embryonic lethal abnormal vision) 
protein family has been identified as regulators of diverse biological processes 
including tumorigenesis [80]. This family includes four members: the 
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ubiquitously expressed protein HuR (also known as HuA, ELAVL1), and three 
neuronal-specific members, HuB (also known as Hel-N1, ELAVL2), HuC 
(ELAVL3), and HuD (ELAVL4). Hu proteins are the vertebrate homologs of 
Drosophila ELAV and were first identified as autoimmune antigens in human 
paraneoplastic neurologic disorders from a subset of small cell lung cancer 
patients who produced anti-Hu antibodies, subsequently attacking Hu protein-
expressing neurons and ultimately causing encephalomyelitis (inflammation of 
brain and spinal cord) and sensory neuropathy [81, 82]. Hu proteins contain four 
functional domains including three RNA recognition motifs (RRM1, RRM2, 
and RRM3) and a hinge domain carrying the HuR nucleocytoplasmic shuttling 
sequence (HNS). RRM1 and RRM2 are thought to recognize and bind to AU-
rich elements (AREs) in the target mRNA transcripts in a cooperative manner. 
On the other hand, RRM3 has been shown to associate with poly(A) sequences 
of mRNAs suggesting that Hu proteins recognize specific ARE-containing 
mRNAs, and simultaneously bind to AREs and the poly(A) tail, to post-
transcriptionally regulate the expression of bound mRNAs. RRM3 is also likely 
to be involved in the formation of the Hu oligomeric complexes that are thought 
be the functional unit of Hu proteins. The small molecule MS-444 that prevents 
HuR homodimerization is a potent inhibitor of HuR’s regulatory function [83].  
               
2.3 Cancer-associated RNA binding protein HuR/ELAV1 and its functions 
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                  The ubiquitously expressed family member, HuR/ELAV1, post-
transcriptionally regulates genes involved in the normal cellular response to 
cancer-associated stressors (e.g., DNA damage, nutrient depletion, hypoxia, and 
therapeutic agents) [60, 80, 84, 85]. When triggered by stress, HuR translocates 
from the nucleus to the cytoplasm, where it potently influences translation of 
key tumor promoting mRNAs through mRNA stabilization and/or direct 
facilitation of translation. HuR’s functions identified thus far include mRNA 
transportation, mRNA stabilization, facilitation of protein translation, and a 
more obscure nuclear function [70]. HuR exerts its main functions through its 
three RNA recognition motifs (RRMs) that interacts with target mRNAs [66]. 
HuR’s target mRNAs usually carry sequences of adenine- and uridine-rich 
elements (AU-rich elements or AREs) located in their 3′-untranslated region 
(UTR), but mRNAs with AREs in the 5’UTR can also be HuR targets [86]. The 
subcellular localization of HuR-mRNA complex is influenced by the post-
translational modifications of the hinge region of HuR, a process controlled by 
numerous cellular mechanisms [87]. The minimal functional ARE sequence is a 
nonamer UUAUUUA(U/A)(U/A) [100]. Numerous RBPs can bind to AREs of a 
mRNA, modulating its half-life [76]. With an estimated 10% of all mRNAs 
bearing AREs [99], HuR can regulate the expression of many genes. However, 
HuR does not bind to and stabilize all ARE-containing mRNAs indiscriminately. 
How HuR recognizes its target ARE-containing mRNAs is less understood. 
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2.3.1 mRNA stabilization 
The most characterized HuR function is its ability to bind to AREs in 
3’UTR of target mNRAs and stabilize them. HuR recognizes AREs that 
typically consist of repeats of the AUUUA pentamer or UUAUUUA(U/A)(U/A) 
nonamer [88]. Most of RBPs, when binding of most RBPs to AU-rich RNA 
elements (AREs), rapidly promotes deadenylation and degradation of substrate 
mRNAs by targeting them to the exosome [76]. RBPs that function in this 
manner include poly(A)-specific ribonuclease (PARN) and deadenylating 
nuclease (DAN) that promote exonucleolyticc degradation of the poly (A) tail of 
target mRNAs, and the proteins tristetraprolin (TTP), KH-type splicing 
regulatory protein (KSRP), and AU-rich element RNA-binding protein 1 (AUF1) 
that binds to 3UTR AREs and target the bound mRNAs to exosome complexes 
for degradation [80, 87]. In contrast, HuR is thought to promoting RNPs for 
binding to AREs in the target mRNAs, thereby preventing their degradation, 
enhancing their stability, and consequently, increasing protein expression. AREs 
having HuR-consensus binding sequences can also be found throughout 
unprocessed mRNAs including in 5’UTRs, exons, and introns [89].  
 
       2.3.2 Translational regulation  
HuR is known to promote and inhibit the translation of several target 
mRNAs. It remains unclear exactly how HuR facilitates protein translation. 
Several mechanisms have been proposed. HuR was reported to associate with 
                                                                                                                                                                                              
 
 
25 
 
internal ribosomal entry sites (IRES) of 5’UTR in XIAP mRNA and directly 
enhance its translation [90]. Translational upregualtion of CAT-1 and 
Cytochrome C mRNAs has been linked to HuR-elicited exclusion of 
translational repressors (e.g., other RBPs and/or miRNAs) [91, 92]. HuR 
translational inhibitory action may be the consequence of disruption of IRESs in 
the 5’UTR of target mRNAs. HuR also binds to 3’UTR of Wnt5a and c-Myc 
mRNAs and represses their translation [93]. HuR inhibition of c-Myc translation 
was reported as a response of HuR’s recruitment of the miRNA, let-7/RISC 
complex, to  the 3’UTR of c-Myc [93]. However, the exact mechanism for 
HuR’s Wnt5a translational repression is not known. Hinman et al. proposed that 
HuR’s stabilization of target mRNA and suppression of mRNA translation can 
occur simultaneously, resulting in negative regulation of translation [80].  
 
       2.3.3 Nuclear function 
HuR’s nuclear functions remain unclear. Using ribonucleoprotein 
immunoprecipitation (RNP-IP) followed by microarray analysis to identify more 
stable native HuR-mRNA targets, Mukherjee et al. discovered that about one-
third of HuR-RNA associations occurs at pre-mRNA introns [89]. Many of these 
associations were detected in the proximity of 3’-splice sites. This observation is 
suggestive of a role that HuR might play in alternative splicing of pre-mRNA 
transcripts. In fact, this idea is supported by reports of HuR’s function in the 
processing of the FAS pre-mRNA (an apoptosis-promoting receptor), and in the 
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production of class-switched antibodies in B cells [94, 95]. It has also been 
proposed that HuR’s high nuclear abundance functions to store nuclear mRNAs 
that are not yet ready for exportation, thus avoiding premature degradation [96]. 
Following cellular damage, HuR likely facilitates the exportation of its mature 
target mRNAs to cytoplasm, a process that still remains poorly understood, 
where HuR exerts its prominent cytoplasmic functions.  
 
 
 
 
       2.4 Regulation of HuR 
HuR’s active functions rely on its post-translational modifications, 
subcellular localization, and the abundance and integrity of HuR protein, all of 
which are tightly controlled by many cellular processes including transcription, 
post-transcription, and post-translation. HuR protein modifications also 
influences the association of HuR and its target mRNAs and localization of HuR 
protein. 
 
       2.4.1 Transcriptional regulation of HuR 
Elevated HuR protein expression and increased HuR cytoplasmic 
location, are frequently observed in many cancer types, including ovarian 
tumors [64, 66, 87, 97, 98]. Given that there have been no genetic mutations, 
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increase of gene numbers, and epigenetic alterations of HuR detected, HuR 
abundance has been linked to the transcriptional control of HuR [88].  However, 
the exact mechanisms that underlie how transcriptional regulation results in HuR 
overexpression remains poorly understood. HuR mRNA has been shown to be a 
target of a transcription factor, nuclear factor kB (NFkB) [88]. In gastric cancer, 
HuR’s overexpression contributes to hyperactive phosphatidylinositol 3-kinase 
(PI3K)/Akt signaling that constantly activates NFkB pathway [88, 99]. In 
addition, SMAD-mediated upregulation of HuR transcription was observed in 
renal epithelial cells stimulated by bone morphogenic protein (BMP) [87, 100]. 
 
       2.4.2 Post-transcriptional regulation of HuR 
Post-transcriptional control of HuR includes HuR auto-regulation and 
HuR’s competition with miRNAs, both of which can affect HuR protein 
expression level [86]. HuR auto-regulation occurs when HuR protein competes 
with mRNA decay-promoting RBPs for binding of AREs that reside in 3’UTR 
of HuR mRNA resulting in mRNA stabilization and enhancement of HuR 
protein translation [66, 101]. Furthermore, association of HuR protein and 
mRNA also enhanced the cytoplasmic export of the HuR mRNA [87]. Two 
miRNAs, miR-519 and miR125a have been shown to associate with HuR 
mRNA and inhibit translation, leading to repressed HuR production [102, 103].  
 
2.4.3 Post-translational regulation of HuR 
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Posttranslational modifications of HuR greatly affect HuR functions 
including its subcellular localization and/or association with target mRNAs. In 
general, HuR subcellular localization is altered through modifications within or 
near the HNS region. HuR binding of target mRNAs is determined by 
modification of residues within the RRMs. The major post-translational 
modifications of HuR are phosphorylation, ubiquitination, methylation, and 
caspase-mediated HuR cleavage (Figure 1) [104-114].    
HuR phosphorylation: A number of kinases phosphorylate HuR at 
different residues. The checkpoint kinase 2 (Chk2) phosphorylates HuR at 
residues Ser-88 (within RRM1), Ser-100 (between RRM1 and RRM2), and Thr-
118 (within RRM2) resulting in modulations of HuR binding of target mRNAs 
[104]. For example, phosphorylation of HuR at Ser-100 by oxidative damage-
induced Chk2 activation triggers the dissociations of HuR from SIRT1 or other 
mRNAs [104]. The G2-phase kinase CDK1 (cdc2) phosphorylates HuR at Ser-
202 within the HNS region leading to the nuclear retention of HuR in 
association with 14-3-3θ, thus hindering its post-transcriptional function [105]. 
HuR phosphorylation at Ser-158 (within RRM2) and Ser-221(within HNS) by 
protein kinase Cα (PKCα) in response to ATP treatment , and at Ser-221 (HNS) 
and Ser-318 (within RRM3) by protein kinase Cδ (PKCδ) in response to 
angiotensin II (AngII), promotes HuR cytoplasmic translocation and its binding 
to target mRNAs [106-108, 115]. The diabetes-related protein kinase Cβ (PKCβ) 
can phosphorylate HuR (the specific residues were not identified) resulting in 
                                                                                                                                                                                              
 
 
29 
 
stabilization of VEGF mRNA [109]. p38 mitogen-activated protein kinase 
(MAPK) phosphorylates HuR at Thr-118 (RRM2) in response to radiation, 
resulting in HuR’s cytoplasmic accumulation and enhanced binding to mRNA of 
the cyclin-dependent kinase inhibitor p21Cip1, subsequently increasing p21 
protein expression and arresting the cell cycle at G1/S phase [110].  
HuR methylation: In response to lipopolysaccharide stimulation of 
macrophages, coactivator-associated arginine methyltransferase 1 (CARM1) 
myethylates HuR at Asp-271 in the HNS region, resulting in stabilization of 
TNF-α mRNA [111].  
HuR ubiquitination: Heat shock promotes HuR ubiquitination at 
residue Lys-182 (within RRM2) followed by proteasome-mediated HuR protein 
degradation, resulting in enhanced cell survival [112].  
Caspase-mediated HuR cleavage: Staurosporin induces a lethal 
apoptotic cell death program involving the apoptotic proteins FADD, caspase-8, 
and caspase-3 and promotes cleavage of HuR at residue Asp-226 (within HNS) 
[113, 114]. The large apoptotic HuR cleavage product (a 24-kDa protein 
fragment, CP1) binds to transportin 2 resulting in blockage of the nuclear import 
of HuR, thereby promoting myogenesis [116]. 
 
2.5 HuR in cancer 
HuR is one of best characterized RBPs involved in carcinogenesis and 
tumor progression [70]. Increased HuR protein has been observed in lymphomas, 
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gastric, breast, pancreatic, prostate, oral, colon, skin, lung, ovarian, and brain 
cancers [117-122]. The cancer biological capabilities (sustained proliferative 
signaling, continuum of cell growth-and-division cycles, enabled replicative 
immortality, survival from apoptotic stimulation, immune evasion, angiogenesis 
development, and invasion and metastasis) that cancer cells acquire during 
tumor development are achieved through genetic modifications (e.g., TP53 
mutations) [57]. Cancer cells constantly receive extracellular and intracellular 
insults from the cancer microenvironment. Cancer cells cannot rely upon rapid 
accumulations of mutations in genes that are needed to survive these insults. 
Instead, cancer cells utilize HuR’s ability to post-transcriptionally regulate 
multiple genes rapidly to ensure survival. HuR regulates numerous mRNAs that 
encode proteins responsible for implementing five major cancer-related traits: 
sustained proliferative signaling, survival from apoptotic stimulation, local 
angiogenesis development, immune evasion, and invasion and metastasis 
facilitation [70]. The HuR-associated hallmarks of cancer constitute an 
organizing network that tightly controls cancer progression and modules the 
complexities of this disease. Some cancer-related mRNAs that are regulated by 
HuR are listed in Table 2. 
 
        2.5.1 Continuous proliferation 
The most fundamental trait of cancer cells is the ability to sustain 
proliferation. In normal cells, the production and release of growth promoting 
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factors is tightly controlled to avoid unnecessary entry into and progression of 
the cell division cycle, thereby ensuring homeostasis of cell number and 
maintenance of normal tissue architecture and function. For a tumor to 
continuously grow, cancer cells must have a constant active proliferative signal.  
Many HuR regulated mRNAs encoded proteins that are involved in cell cycle 
progression and cell division. 1) HuR positively regulates many cyclins that 
activate cyclin-dependent kinases (Cdks) controlling cell cycle phases. Cyclin 
D1 is an essential activator of Cdk4 and Cdk6 which facilitate cell cycle 
progression through G1 phase. HuR associates with the 3’UTR of cyclin D1 
mRNA, and stabilizes it in human cervical carcinoma cells [123]. Cyclin E1, an 
activator of Cdk2 participating in the progression through G1/S transition, is 
associated with HuR leading to increased protein expression in the breast cancer 
cells [124, 125]. HuR also interacts with the 3’UTR of cyclin A2, another Cdk2 
cofactor that promotes cell cycle progression through S phase and promotes its 
expression in colon cancer cells [126]. Similarly, through the association of HuR 
with the mRNA 3’UTR of cyclin B1, an activator of Cdk1 for progression 
through the G2 phase, the mRNA is stabilized in colon cancer cells [126]. 2) 
HuR negatively regulates the process of cellular senescence, a tumor 
suppressive mechanism that facilitate the cessation of cell cycle. p27 prevents 
cell proliferation through inhibition of Cdk2. HuR associates with the 5’UTR of 
p27 mRNA, disrupting the activity of an IRES, thereby inhibiting p27 
translation [127].  3) HuR regulates other proteins that have the capability to 
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promote cell proliferation. Epidermal growth factor (EGF) promotes cell 
proliferation through activation of proliferative signaling pathways; its mRNA is 
associated with HuR. Eukaryotic translation initiation factor (eIF4E) is elevated 
in many human cancers. HuR binds to the 3’UTR of eIF4E mRNA, thereby 
stabilizing it and increasing its protein expression [128]. Deoxycytidine kinase 
(dCK), a metabolic enzyme that phosphorylates deoxyribonucleosides and 
nucleoside analogs, facilitates DNA synthesis and cell proliferation.  HuR binds 
to and stabilizes the 3’UTR of dCK mRNA promoting protein translation in 
pancreatic cancer cells [85].  
 
 
       2.5.2 Survival from apoptotic stimulation 
     Programmed cell death is a powerful mechanism that cells use to 
negatively regulate cell proliferation. In addition to the hallmark capability of 
inducing and sustaining growth-stimulatory signals, cancer cells must also 
circumvent the powerful apoptotic programs that negatively regulate cell 
proliferation. Many cellular proliferative signals are kept at bay by the actions of 
tumor suppressor proteins. Some tumor suppressors are known to be upregulated 
by HuR. These include ProTα, Bcl-2, Mcl-1, SIRT1, p21, XIAP and Mdm2. In 
addition, HuR binds to c-Myc mRNA and negatively regulates the translation of 
Myc protein which can have a pro-apoptotic function. The recently identified 
HuR targets, WEE1 and PIM1, are involved in cell survival following drug 
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treatment of pancreatic cancer cells [129, 130]. HuR associates with 3’UTRs of 
WEE1 and PIM1 mRNAs, and promotes their expression. Furthermore, 
expression of death receptor 5 (DR5) that triggers the extrinsic apoptotic 
pathway upon binding of  TNF-related apoptosis-inducing ligand (TRAIL) is 
negatively regulated by HuR in pancreatic cancer cells [131]. HuR binds to the 
5’UTR of DR5 mRNA, subsequently repressing DR5 protein expression.  
 
2.5.3 Enhancement of angiogenesis 
           Another hallmark of cancer is the development of tumor-associated 
neovasculature. Like normal tissues, tumors generate metabolic energy from 
nutrients and oxygen and produce metabolic wastes and carbon dioxide, both of 
which are supplied and carried by blood vessels generated by the process of 
angiogenesis.  Cancer cells rapidly grow into a tumor mass that requires a huge 
blood supply. In normal tissues angiogenesis is often inactive, except in some 
physiologic processes such as wound healing and the female reproductive cycles. 
In tumor progression, however, angiogenesis is almost always activated and 
remains on, causing quiescent vasculature reactivation and continual growth of 
new blood vessels that help to sustain neoplastic growth. HuR binds to mRNAs 
of potent pro-angiogenic factors HIF-1α, VEGF, and COX-2 and promotes their 
protein expression. Moreover, HuR’s association with mRNA of an 
angiogenesis inhibitor thrombospondin-1 (TSP1) causes reduction of TSP1 
expression.  
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2.5.4 Activation of invasion and metastasis 
Epithelial derived carcinoma progressing to higher pathological grades 
of malignancy is reflected by local invasion and distant metastasis. The local 
microenvironment plays an important role in cancer development. A major 
component of the microenvironment is the extracellular matrix (ECM), a 
network composed of a large collection of proteins, glycoproteins, 
proteoglycans, and polysaccharides having different physical and biochemical 
properties. Cancer cells secrete factors and chemokines to alter their attachment 
to each other and to the ECM and to modify the ECM to become a tumorigenic 
microenvironment. Dysregulated and disorganized ECM can facilitate tumor 
progression. HuR facilitates the expression of extracellular proteases and 
proteins to alter the interaction between cancer cells and their local 
microenvironment and promote epithelial-to-mesenchymal transition. Those 
HuR-regulated targets involved in invasion and metastasis include mRNAs 
encoding Snail, MMP-9, uPA and the uPA receptor.  
 
2.5.5 Reduction of immunesurveillance 
Immunesurveillance is one of the protective mechanisms cells impose 
to inhibit carcinogenesis and to maintain cellular homeostasis. The process 
eliminates nascent transformed cells by activating immune effector cells such as 
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NK cells and by releasing IFN-γ in an innate immune response. Tumor cells, 
however, produce tumor-derived soluble factors (TDSFs) to induce several 
mechanisms to promote escape from immune attack, allowing tumors to 
progress and metastases. One TDSF, transforming growth factor- β (TGF-β), is a 
cytokine that enables tumor cells at an advanced stage to escape immune 
recognition [132]. HuR binds to 3’UTR of TGF-β mRNA, and post-
transcriptionally regulates its expression in brain tumors [133]. The mitogen-
activated protein (MAP) kinase phosphatase 1 (MKP-1) is a nuclear-localized 
phosphatase that dephosphorylates proteins, thereby inactivating the MAPKs 
ERK, p38, and c-Jun NH2-terminal kinase (JNK) [134]. Overexpression of 
MKP-1 blocks the lipopolysaccharide (LPS)-triggered production of 
proinflammatory cytokines by inhibiting p38 [135]. HuR binds to and promotes 
expression of MKP-1 [136]. 
Table 1: Examples of RNA-binding proteins (RBPs) and microRNAs involved in post-
transcriptional gene regulation 
 
Process RBPs microRNAs 
Alternative splicing Sam68, Serine/arginine-rich (SR) 
proteins, Heterogeneous RNPs 
(hnRNPs), Exonic splicing 
enhancers (ESEs) [76, 137] 
 
miR-23a/b [138] 
RNA modification Adenosine deaminase, RNA-
specific (ADAR) [139] - 
Polyadenylation Cleavage and polyadenylation 
specificity factor (CPSF), 
Cleavage stimulation factor 
(CstF), Polyadenylate 
polymerase (PAP), Cleavage 
factor I and I (CFI and CFII), 
miR-125b and let-7 [142] 
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and poly(A) binding protein 
(PABP) 
[140, 141] 
mRNA export Poly(U) binding protein 1 (Pub1), 
nuclear poly(A) binding protein 2 
(Nab2) [143] 
- 
mRNA localization She2p, Zipcode-binding 
protein 1 (ZBP1) [144, 145] 
miR-122 [146] 
Translation T-cell-restricted intracellular 
antigen 1 (TIA-1), TIA-1-related 
protein (TIAR),  Zipcode-
binding protein 1 (ZBP1) [145, 
147]  
Let-7, miR-122 [146, 148] 
mRNA turnover Tristetraprolin (TTP), AU-
binding factor 1 (AUF1), KH-
type splicing regulatory protein 
(KSRP), Butyrate response 
factor 1 (BRF1) [149-153] 
 
miR-196 [154] 
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Figure 1. Post-translational modification of HuR and its function in post-transcriptional 
regulation. RRM: RNA recognition motif, HNS:HuR nucleocytoplasmic shuttling, 
ARE:AU-rich RNA element 
Source: Front Biosci (Landmark Ed). 2012 Jan 1;17:189-205. 
 
Table 2: Example of HuR-regulated mRNA transcripts involved in hall marks of cancer 
 
HuR-regulated hall 
marks of cancer 
Selected HuR 
target mRNA 
HuR 
binding site 
HuR influence on mRNA Related cancer 
Proliferation Cyclin D1 [118] 3’UTR Stability ↑ Oral cancer 
Cyclin E1 [124] 3’UTR Stability ↑ Breast cancer 
Cyclin A2 [118, 
126, 155] 
3’UTR Stability &translation↑ Oral, gastric, colon 
Cyclin B1 [118, 
126] 
3’UTR Stability ↑ Oral cancer 
P27 [127] 5’UTR Translation ↓ Cervical cancer 
EGF [128] 3’UTR Stability ↑ Prostate cancer 
eIF4E [156] 3’UTR Stability ↑ Pharyngeal 
Survival 
 
ProTα [157] 3’UTR Translation ↑ Cervical 
Bcl-2 [59, 158] 3’UTR Stability &translation↑ Cervical, prostate, 
epidermoid cancer 
Mcl-1 [59] n.d. Stability ↑ Cervical cancer 
SIRT1 [104, 159] 3’UTR Stability ↑ Cervical, prostate 
P21 [160, 161] 3’UTR Stability ↑ Brest, colon cancer 
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c-Myc [93] 3’UTR Translation ↓ Cervical cancer 
Caspase 9 [162] 3’UTR Stability ↑ Cervical cancer 
Immunity 
 
IL8 [133, 163] 3’UTR Stability ↑ Breast, and glioma 
IL-6 [133] 3’UTR Stability ↑ Malignant glioma 
TFGβ [133] 3’UTR Stability ↑ Malignant glioma 
TNFα [133] 3’UTR Stability ↑ Malignant glioma 
Angiogenesis 
 
TSP1 [164] 3’UTR Translation ↑ Breast cancer 
HIF-1α [165] 5’UTR, 
3’UTR 
Stability &translation↑ Cervical cancer 
VEGF [166] 3’UTR Stability &translation↑ non-small cell lung 
iNOS [167] 3’UTR Stability ↑ Colon cancer 
COX-2 [118, 159, 
168-170] 
3’UTR Stability ↑ Colon, ovarian, 
gastric, oral, 
prostate 
Invasion and 
metastasis 
 
uPA [171] 3’UTR Stability ↑ Breast cancer 
uPAR [171] 3’UTR Stability ↑ Breast cancer 
MMP-9 [172, 173] 3’UTR Stability ↑ Fibrosarcoma, 
myeloid leukemia 
Snail [174] 3’UTR Stability ↑ Breast cancer 
n.d.: not determined 
Source: Front Biosci (Landmark Ed). 2012 Jan 1; 17:189-205. Wiley Interdiscip Rev 
RNA. 2010 Sep-Oct; 1(2):214-29 
Chapter 3 
Opportunities for siHuR targeted therapy and utilization of HuR 
as a predictive marker for gemcitabine treatment in ovarian 
cancer.  
The conventional way in developing new cancer treatments is to target 
inhibition, by short hairpin RNA or small molecules, of an aberrantly expressed 
protein found in cancer cells. For example, Bevacizumab, a humanized 
monoclonal antibody inhibits vascular endothelial growth factor A (VEGF-A) 
and Panitumumab, a human monoclonal antibody targets ErbB2/HER2. The 
major drawback of this strategy is that cancer cells, although initially susceptible 
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to the inhibition, can quickly activate overlapping signal pathways to surpass the 
blockage, rendering the treatment ineffective. An improved strategy is to 
identify a protein that is not only overexpressed in cancer cells, but also 
functions in the regulation of multiple signal pathways and is amenable to 
targeted intervention. By inhibition of multiple signal pathways at once, the 
treatment has a good chance to be effective. A qualified candidate in ovarian 
cancer cells is HuR which post-transcriptionally regulates critical genes 
involving in many aforementioned cancer traits. Previously, it has been shown 
that HuR expression is a predictive marker in ovarian cancers; increased HuR 
expressions have been associated with invasive ovarian cancer, high tumor 
grade, and decreased disease-free survival [169, 175, 176]. When triggered by 
stress, HuR translocates from the nucleus to the cytoplasm where it potently 
influences translation of key tumor promoting genes by mRNA stabilization and 
direct facilitation of translation. HuR’s abilities to enable tumor cells to 
proliferate and to survive against stressful stimuli suggest its potent role in 
modulating gene expression and potential as a prime target for ovarian cancer 
treatment. One approach to inhibit HuR is through targeted delivery of 
functional small interfering RNA (siRNA).  
 
      3.1 siRNAs as a therapeutic regime  
In comparison with monoclonal antibodies (typically targeting 
extracellular proteins) and small molecules (generally targeting G protein 
                                                                                                                                                                                              
 
 
40 
 
coupled receptors, ion channels, enzymes and nuclear hormone receptors), 
siRNA induced protein inhibition possesses several advantages. First, with 
specifically designed sequences, siRNAs can target and silence any gene, 
including so-called “undruggable targets”. Second, the siRNA-based RNA-
induced-silencing complex (RISC) acts catalytically on its targets rather than 
stoichiometically as do small molecules. As a consequence, the target is 
destroyed rather than inhibited. Thus, less drug might be required, hereby 
decreasing potential side effects. Third, siRNAs act upstream of protein 
translation, directly cleaving target mRNAs, a feature that leads to less drug 
being required. Fourth, identification, optimization, and synthesis of siRNAs are 
fast, and the candidate siRNA molecules can be numerous. Although there are 
great practical benefits using siRNAs as therapeutics, the challenge of siRNA 
delivery is the greatest limitation in the clinic. 
       3.2 siRNA delivery 
There are several challenges in delivery of functional siRNAs in vivo. 
In order to get siRNAs across the tightly packed hydrophobic cell membrane, 
the relatively large and charged siRNA molecules must be disguised by carriers. 
Ideal siRNA carriers have the ability to 1) protect the therapeutic payload 
(siRNAs) from degradation, filtration, and cell-mediated phagocytosis in the 
blood circulation system; 2) facilitate transport across the vascular endothelial 
barrier; 3) pass through the extracellular matrix; 4) promote cellular uptake; 5) 
release the siRNA into cytoplasm.   
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Viruses are biological delivery vehicle that have been shown to deliver 
DNA very effectively, but they cannot carry and deliver siRNAs. Moreover, 
safety concerns such as immunogenicity and insertional mutagenesis have led to 
the design, synthesis, and formulation of non-viral carriers. The design of 
engineered synthetic siRNA delivery systems must consider binding to the 
anionic polyphosphate backbone of siRNAs, and formation of nanometer-sized 
particles that are stable and can enhance cellular uptake. Several formulations 
that have been made as carriers of siRNA for the treatment of ovarian cancer 
include lipidoids, neutral liposomes, and tumor-penetrating nanocomplexes 
(TPNs) [177]. 
Lipidoid-based siRNA formulations consist of lipidoid, cholesterol, 
polyethylene glycol-lipid (PEG-lipid), and target siRNA. Lipidoids are 
synthesized by addition of acrylamide or acrylates to amines [178]. One 
example of using lipidoid to deliver siRNAs to treat ovarian cancer is the 
lipidoid/Claudin-3 (CLDN3) therapy [179]. CLDN3, highly expressed in 
ovarian tumors, is an integral membrane protein associated with tight junctions 
[180, 181]. High amounts of CLDN3 are associated with increased cellular 
motility and survival of ovarian tumor cells, and an increase in matrix 
metalloproteinase type 2 (MMP-2) [182], implicating a role for CLDN3 in 
ovarian tumorigenesis and metastasis. i.p. delivery of lipidoid/CLDN3-siRNA to 
ovarian tumors in 3 mouse models for ovarian cancer significantly suppressed 
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tumor growth and ascites development, compared to mice treated with control 
siRNA [179, 183]. 
Neutral liposome 1, 2-dioleoyl-sn-glycero-3-phosphatidylcholine 
(DOPC) has been used to deliver siRNA targeting the oncoprotein EphA2, a 
highly expressed tyrosine kinase associated with poor clinical outcome, in an 
orthotopic mouse model of ovarian cancer [184]. Treatment with DOPC/EphA2-
targeting siRNA reduced tumor growth compared with the treatment of control 
siRNA [184]. Furthermore, when combined with paclitaxel, DOPC/EphA2-
targeting siRNA dramatically reduced tumor growth as compared to growth in 
mice treated with  paclitaxel and control siRNA [184].  
Tumor-penetrating nanocomplexes (TPNs) contain tandem peptides 
that consist of a cyclic tumor-penetrating domain (LyP-1) and various cell-
penetrating peptide domains separated by a 4-glycine spacer [185]. N-
myristoylation (myr) enhances hydrophobic interactions and peptide affinity to 
the cell membrane. Target siRNAs are electrostatically bound to the tandem 
peptides [185]. TPNs have been used to deliver siRNA targeting inhibition of 
DNA binding 4 (ID4), a novel oncogene that is amplified in one third of high-
grade serous ovarian cancer [186]. Treatment of ovarian tumor-bearing mice 
with TPN/ID4 targeting siRNA suppressed tumor growth and significantly 
improved survival [186].  
A newly developed siRNA in vivo delivery system, 3DNA nanocarrier, 
is a 3-dimensional structure made entirely out of DNA. A detailed discussion of 
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3DNA nanocarrier properties and functionality including biodistribution, 
immunogenic, and effectiveness for delivery of siRNAs are described in Chapter 
4.4.  
 
      3.3 Intraperitoneal delivery of siHuR 
Given that ovarian cancer develops, progresses, and metastasizes 
within the peritoneal cavity regardless of various histosubtypes, makes treatment 
of this complex disease amenable to intraperitoneal (i.p.) administration of 
therapeutics. Moreover, i.p. administration increases effective drug 
concentration at the site of peritoneal diseases and decreases toxicity through 
systemic treatment. I.p. administration of paclitaxel nanoparticles has been 
shown to inhibit the progression of ovarian carcinoma in rats [187]. In the clinic 
setting, i.p injection of the standard treatment for ovarian cancer, cisplatin and 
paclitaxel, achieved improved outcomes compared to i.v. injections [188]. 
Furthermore, it is noteworthy that i.p. chemotherapy for advanced ovarian 
cancer improves overall and disease-free survival as compared to i.v. 
administration [189]. This finding was the basis for a rare Clinical 
Announcement posted by the National Cancer Institute in January 2006 
recommending that physicians use this mode of drug administration in treating 
ovarian cancer patients [190]. Moreover, the efficacy of nanoparticle-mediated 
siRNA delivered intravenously is directly related to the tumor vascularity [191], 
and i.p. administration can impart vascular-independent siRNA exposure to 
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ovarian tumors. We reasoned that i.p. delivery of siHuR nanoparticles would 
avoid biodistribution complications associated with i.v. injection of 
nanoparticles and would therefore allow their access to metastatic tumors in the 
peritoneal cavity where most metastatic ovarian tumors are located. 
  
       3.4 Folate receptor:  targeting ovarian cancer  
Targeted delivery is achieved through ligand-receptor binding. By 
attaching a targeting ligand to the surface of nanoparticles, the targeted delivery 
can increase interaction between nanoparticles and the cell, and avoid non-
specific binding. Compared to normal tissues, folate receptor-α (FRα), is highly 
expressed in many cancer; in particular, it is overexpressed in 85-90% of 
ovarian cancer [192, 193]. Moreover, FRα overexpression correlates with 
ovarian cancer histological grades [192]. FRα is a transmembrane receptor 
which internalizes through endocytosis upon binding to its ligand, folic acid 
[194]. The internalization of FRα-folic acid complex effectively deposits entities 
associated with it (e.g., nanoparticles) to the cytosol, while the receptor is 
recycled and transported back to the cell membrane [194]. Hence, FRα is a 
suitable homing device that provides a selective gate for targeted delivery of 
therapeutics, including siHuR, to ovarian cancer cells. 
 
3.5 Exploration of the potential of HuR to serve as a predictive marker for 
gemcitabine efficacy in ovarian cancer treatment 
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Gemcitabine (2, 2 –difluorodeoxycytidine; dFdC) is a nucleoside 
analogue of deoxycytidine, the standard treatment choice for advanced and 
metastatic pancreatic cancer [195]. Gemcitabine has also been adopted to treat 
many tumors including ovarian cancer, especially when combined with the 
platinum-based chemotherapeutics, cisplatin and carboplatin [56]. Gemcitabine 
is a prodrug as it requires phosphorylation to its the active triphosphate form, 2’, 
2’-difluoro-20-deoxycytidine triphosphate; dFdCTP [195]. Cellular uptake of 
gemcitabine is mediated by human equilibrative nucleoside transporters 
(hENTs), mainly by hENT1 which facilitates the transport of hydrophilic 
nucleosides and nucleoside analogs across the cell membrane [195]. hENT1 
expression varies in ovarian primary and cancer cell lines (Figure 1). Once in the 
cell, gemcitabine is first phosphorylated by deoxycytidine kinase (dCK) to the 
monophosphate (dFdCMP) and then subsequently phosphorylated by pyrimidine 
nucleoside monophosphate kinase (UMP-CMP kinase) to yield gemcitabine 
diphosphate (dFdCDP) which is subjected to the final phosphorylation into the 
active metabolite gemcitabine triphosphate (dFdCTP) [195]. The enzyme in the 
final phosphorylation step is unclear, but it is thought nucleoside diphosphate 
kinase may play this role [196]. Gemcitabine and gemcitabine monophosphate 
are inactivated by cytidine deaminase (CDA) and deoxycytidylate deaminase 
(dCTD), respectively [195]. The product of dCTD is dFdU monophosphate 
(dFdUMP) that inhibits the activity of thymidylate synthase, subsequently 
affecting the deoxynucleotide triphosphate (dNTP) pool [195].     
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The primary cellular effect of gemcitabine is to inhibit DNA synthesis. 
As a consequence of its lack of 2’-OH, when dFdCTP is incorporated into DNA, 
DNA chain elongation arrested due to the inability of DNA polymerase to 
proceed, a process known as “masked chain-termination”. Another important 
gemcitabine cellular action is to induce apoptosis through caspase-dependent 
signaling. Gemcitabine-induced cellular stress activates p38 mitogen-activated 
protein kinase (MAPK) to trigger apoptosis [197]. Activated p38-MAPK has 
been shown to induce phosphorylation of heat shock protein 27 (Hsp27), a 
chaperone that is involved in the unfolded protein response, leading to growth 
suppression [198]. Another action of gemcitabine is through covalent binding of 
gemcitabine diphosphate to the active site of ribonucleotide reductase (RR), a 
key enzyme in DNA replication and for DNA repair.  
The unique therapeutic cellular mechanism of gemcitabine and its 
favorable toxicity profile make this drug a potent candidate for combination 
chemotherapy.  In fact, gemcitabine is currently being used in combination 
with platinum-based drugs to treat recurrent ovarian cancer [56].  Treatment of 
gemcitabine plus carboplatin has been shown to significantly improve 
progression-free survival (PFS) and response rate compared to carboplatin-only 
treatment without worsening quality of life in patients with platinum-sensitive 
recurrent ovarian cancer [56]. The mechanism underlying the synergism 
between gemcitabine and carboplatin is based on the increased platinum-DNA 
adducts induced by gemcitabine incorporation into DNA [56].  
                                                                                                                                                                                              
 
 
47 
 
The rate-limited enzyme in the production of active gemcitabine 
metabolite is considered to be dCK. Two studies have shown that high 
cytoplasmic expression of HuR in pancreatic ductal adenocarcinoma cells in 
culture dramatically sensitizes cells to gemcitabine [85, 97]. In addition, in small 
cohorts of pancreatic cancer patients treated with gemcitabine following surgery, 
a significant association between increased overall survival and high HuR 
expression in the cytoplasm has been identified, suggesting that HuR subcellular 
localization might serve as a predictive marker for gemcitabine response [85, 
97]. Enhanced gemcitabine functionality in tumors is likely the consequence of 
increased production of dCK resulting from post-transcriptional regulation of 
dCK mRNA by HuR [85, 97, 199, 200]. In a study we conducted, we sought, 
but found no evidence, that HuR cellular localization might serve as a predictive 
marker for clinical outcome following gemcitabine treatment of recurrent 
ovarian tumors (see Chapter 5).  
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Figure1. Western Blot analyses of HuR and hENT1 in ovarian primary cells 
(HIO80 and HIO120), and cancer cells (A2780, ES2, OVCA420, OVCAR3, and 
OVCAR5) 
 
 
 
 
 
 
 
Chapter 4 
Delivery of Therapeutics Targeting the mRNA-Binding Protein 
HuR Using 3DNA Nanocarriers Suppresses Ovarian Tumor  
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4.1 Abstract  
Growing evidence shows that cancer cells use mRNA-binding proteins and 
microRNAs to post-transcriptionally regulate signaling pathways in order to 
adapt to harsh tumor microenvironments (e.g., hypoxia and chemotherapeutic 
exposure). In ovarian cancer, cytoplasmic accumulation of mRNA-binding 
protein HuR (ELAVL1) is associated with poor prognosis. In this study, we 
observed high HuR expression in ovarian cancer cells as compared to ovarian 
primary cells, providing a rationale for targeting HuR.  Silencing HuR in ovarian 
cancer cells in culture by transient transfection of small interfering RNA 
(siHuR) or by stable expression of short hairpin RNA (shHuR), significantly 
decreased cell proliferation and anchorage-independent growth, and impaired 
migration and invasion. Human ovarian xenografts expressing shHuR were 
smaller than control tumors. A biodistribution study showed effective tumor-
targeting by a novel Cy3-labeled folic acid (FA)-derivatized DNA dendrimer 
nanocarrier (3DNA®). Systemic administration of siHuR-conjugated FA-3DNA 
to ovarian tumor-bearing mice suppressed tumor growth and ascites 
development, and significantly prolonged lifespan. NanoString gene expression 
analysis identified multiple HuR-regulated genes as evidenced by changes in 
their expression upon HuR inhibition. These HuR-regulated genes function in 
multiple essential cellular molecular pathways, a finding that sets this 
therapeutic approach apart from other therapies that target a single gene. These 
results are the first to demonstrate the versatility of the 3DNA nanocarrier for in 
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vivo targeted delivery of a cancer therapeutic, support the notion that HuR is a 
promising target, and support the potential use of FA-derivatized 3DNA 
dendrimer for siHuR targeted delivery to ovarian tumor cells for treatment of 
advanced ovarian cancer patients.  
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2 Introduction  
              Ovarian cancer is the second most common gynecological cancer in the 
United States. It has been perceived as a silent killer due to its asymptomatic 
nature during the early stages of disease progression. Ovarian cancers are 
classified into a number of different subtypes depending on cellular origin and 
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histologic characteristics, epithelial ovarian cancer being by far the most 
common type [201]. The current clinical regimen for treating ovarian carcinoma 
is typically surgical debulking followed by chemotherapy with paclitaxel and a 
platinum-based therapy (cisplatin or carboplatin). Although eighty percent of 
patients receiving this treatment have an initial favorable response, most tumors 
will eventually relapse accompanied by the development of chemoresistance. A 
more effective therapeutic strategy is clearly needed to treat this deadly cancer. 
           Gene dysregulation is a hallmark of cancer. Cancer cells acquire a 
unique gene expression profile in order to continue to proliferate and survive the 
harsh tumor microenvironment. Unlike genetic modification that usually takes 
years to achieve, cancer cells adopt a more rapid and efficient way to alter gene 
expression through regulation of transcribed mRNAs [60-62]. Post-
transcriptional regulation (i.e., modification of mRNA stability and/or 
translational efficiency) is achieved through a tightly controlled network of 
interactions between specific target mRNAs with trans-acting microRNAs 
(miRNAs) and/or RNA-binding proteins (RBPs) [71, 202, 203]. By regulating 
these interactions, cancer cells rapidly alter the stability and/or translational 
efficiency of a large subset of mRNAs that encode proto-oncogenes, cytokines, 
cell cycle regulators and other regulatory proteins that promote cancer cell 
survival and tumor progression [64, 204-206]. 
         HuR (Human antigen R, aka ELAVL1) is a ubiquitously expressed 
RNA-binding protein that is highly expressed in many cancers, including 
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ovarian tumors [176, 207]. HuR functions in normal, healthy cells as a critical 
molecule involved in post-transcriptional gene regulation. When cells are 
stressed (e.g., by low oxygen levels), HuR binds to AREs, AU-rich RNA 
elements typically located in 3’-untranslated regions (UTRs) of mRNAs, and 
potently influences translation of key survival and growth-related mRNAs in the 
cytoplasm by several mechanisms including active transport of mRNAs out of 
the nucleus, mRNA stabilization, and direct facilitation of translation. HuR’s 
role in the stress response is most likely part of a survival mechanism used by 
the most aggressive cancer cells in a tumor [66, 70, 87]. High cytoplasmic HuR 
expression correlates with high histological grade of ovarian cancer and poor 
prognosis in serous ovarian cancer [169, 207].  
   Identification and targeted inhibition of a single protein involved in 
tumorigenesis and tumor progression is one strategy to treat ovarian cancer 
[208]. HuR’s role in post-transcriptional regulation of multiple genes that 
promote survival of ovarian tumor cells provides an opportunity to develop an 
alternative strategy that targets multiple core signaling pathways at once. Indeed, 
proof-of-concept studies using HuR knock-out mice and intracranial injection of 
mice with genetically-silenced HuR primary glioblastoma cells have shown a 
reduction in colon tumor and glioblastoma growth, respectively [121, 209]. One 
approach to inhibit HuR is through targeted delivery of functional small 
interfering RNA (siRNA). We have recently reported suppression of pancreatic 
xenograft growth in mice following direct injection of tumors with a 
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nanoparticle-delivered siHuR [210]. Targeting systemically administered 
siRNA-based therapies to tumor cells, however, has been challenging. To 
address this challenge, in this study, we use a novel DNA dendrimer nanocarrier, 
3DNA®, derivatized with folic acid for systemic administration to target siHuR 
delivery to tumors in mice bearing ovarian tumors that have high cell surface 
expression of folate receptor-α.  
 
4.3 Materials and Methods 
4.3.1 Cell Culture, transfection, and viability assay 
A2780 cells (T. Hamilton, Fox Chase Cancer Center, obtained 2004) and 
OVCAR-5 cells (A. Klein-Szanto, Fox Chase Cancer Center, obtained 2013) 
were authenticated and maintained in RPMI-1640 medium (Cellgro) 
supplemented with 10% FBS (Gemini) at 37°C in 5% CO2. OVCAR3 cells, 
purchased from American Type Culture Collection (ATCC), were grown in 
media as recommended by ATCC. ID8 cells (K. Roby, U. of Kansas Medical 
Center, obtained 2006), stably transfected with CAG/firefly luciferase [179], 
were authenticated and maintained as described [211]. Frozen aliquots of cells 
were prepared upon receipt. All cells were used within 6 months of testing 
negative for mycoplasma using a PCR kit (Sigma). Cells were transiently 
transfected with siHuR (Ambion #4407268) using Lipofectamine 2000 
(Invitrogen). Viable cell number was determined using EZ Count Kit (Lankenau 
Development, Inc.). 
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4.3.2 Immunoblotting  
 Whole cell extracts were prepared in RIPA buffer containing proteinase 
inhibitors. Extract protein concentrations were determined using the BCA 
Protein Assay Kit (Pierce, Rockford, IL).  Soluble proteins were separated on 
10% SDS-PAGE gels and analyzed by Western blotting using HuR monoclonal 
antibody clone 3A2 (1:1000; Santa Cruz Biotechnology), or GAPDH 
monoclonal antibody clone 5C6 (1:8000; Ambion), and a secondary antibody, 
horseradish peroxidase-labeled goat anti-mouse (1:8000, Thermo Scientific). 
Membranes were developed with ECL (Pierce). 
 
4.3.3 Immunostaining 
           Four µm sections of fixed tumors were deparaffinized, antigen retrieval 
was performed using citrate buffer, and endogenous peroxidase was quenched. 
Sections were incubated with primary antibody overnight at 4°C [HuR 
monoclonal antibody 19F12 (1:5000; Clonegene); rabbit anti-Ki-67 (1:150; 
Zymed), then biotinylated secondary antibody for 30 min at room temperature. 
Signal was amplified and visualized using the TSA-Plus Fluorescence System 
(Perkin Elmer) or avidin/biotin complex system (VECTASTAIN Elite ABC kit, 
Vector Laboratories) followed by DAB visualization and hematoxylin 
counterstaining. Sections were viewed with a Zeiss Axiovert 200M microscope. 
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4.3.4 HuR knockdown cell line generation   
            HuR stable knockdown cell lines. To generate shHuR- or shControl 
(shCtrl)-expressing lentiviruses, Lipofectamine 2000 (Invitrogen) was used to 
transfect 293T cells for 24h with plasmids including a HuR shRNA lentiviral 
construct (called shHuRc257; “c” for constitutive) or a control shRNA construct 
(A. Ristimäki, University of Helsinki, Finland) [212], packaging plasmids 
(pRSV-Rev and pMDLg/pRRE), and a VSVG-coding envelope vector (J. 
Azizkhan-Clifford, Drexel University). Transfection mixture was replaced with 
fresh cell growth medium (DMEM + 10% FBS). Forty-eight hours post 
transfection, supernatant was collected, sterile-filtered, and used to infect A2780 
and OVCAR5 in medium containing 8ug/ml polybrene (Santa Cruz). Following 
viral infection, shHuRc257- or shCtrl-expressing cells were selected in medium 
containing hygromycin B (Gemini).  
        DOX-inducible HuR knockdown cell lines. To generate short hairpin RNA 
(shRNA)-expressing plasmids, two DNA oligonucleotides encoding shRNA 
targeting different human HuR sites (referred to as shHuRi289 and shHuRi699; 
“i” for inducible) (Integrated DNA Technologies) were cloned into Tet-pLKO-
puro lentiviral plasmid (J. Azizkhan-Clifford, Drexel University) as described 
by Wiederschain et al [213].  Final shHuR plasmid constructs were confirmed 
by DNA sequencing. Targeted sense sequences were: shHuRi289 = 5’-
GCAGCAUUGGUGAAGUUGAAUCU-3’; shHuRi699 = 5’-
GCCCAUCACAGUGAAGUUUGCA-3’.  To generate OVCAR3 Dox-
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inducible cells, OVCAR3 cells were infected with shHuRi289- or shHuRi699-
expressing lentivirus in medium containing 8 µg/ml polybrene (Santa Cruz). 
Following viral infection, shHuR- or shCtrl-expressing cells were selected in 
medium containing 1µg/ml puromycin dihydrochloride (Gemini).  
 
4.3.5 In vitro scratch assay, soft agar colony formation, and invasion assay  
       7.5 X 105 cells were seeded in 6-well culture plates to ensure 100% 
confluent growth the next day.  The cell monolayer was scratched with a p200 
pipet tip.then rinsed with DPBS to remove debris, followed by addition of fresh 
culture medium containing 5% FBS. Sixteen hours later, photographs of the 
scratches were taken. The mean width of each scratch was measured.  
 The soft agar assay was performed as previously described [214]. Matrigel 
invasion was performed using Corning’s Cell Invasion Assay protocol as 
described [210].  
 
4.3.6 Cell Injection to generate tumors 
       To generate xenografts, 2 X 106 OVCAR5-shHuR or OVCAR5-shCtrl 
cells suspended in 100 µl PBS containing 20% cold Matrigel (BD Biosciences) 
were injected s.c. in the flank of 8 wk-old female athymic nude mice (Harlan). 
Once a week, calipers were used to measure tumor length (L), and width (W), 
and tumor volumes were estimated by the formula V = (L x W2) X 0.52.  
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 To generate tumors in the peritoneum, 6-8 wk-old female C57BL/6J mice 
(Jackson Laboratory) were injected i.p. with 2 X 106 ID8-Fluc cells in 200 µl 
DMEM containing no supplements. To assess tumor growth, mice were 
optically imaged using an IVIS 100 series Bioluminescence Imaging System 
(Caliper Life Sciences) as described previously with a 5-min integration time for 
image acquisition [179]. Luciferase activity, a measure of tumor load, was 
quantified as relative light units (RLU).  
 
4.3.7 3DNA-siHuR formulations and administration  
Dendrimer production. Two layer 3DNA® nanocarriers (Genisphere) were 
prepared having 2 unique single stranded sequences (arms) presented on the 
outer surface as previously described [215, 216]. The diameter, determined by 
DLS, was 70 nm and the zeta potential was -28 +/- 2 meV. Folic acid (FA)-
targeted 3DNA reagents were prepared by first conjugating FA to an 
oligonucleotide having complementarity to one of the 2 single-stranded 
sequences on the surface of the 3DNA and hybridizing this FA-modified 
oligonucleotide to 3DNA nanocarrier to achieve a final ratio of 6 FA molecules 
per 3DNA molecule. FA-targeted 3DNA or untargeted 3DNA was combined 
with either a Cy3 (GE Healthcare) labeled oligonucleotide complementary to the 
second outer surface 3DNA, or a modified siHuR [Integrated DNA 
Technologies (IDT)] or control siRNA (IDT), complementary to the second 
outer surface oligo to prepare fluorescent-tagged or silencing reagents, 
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respectively. Both the siHuR and control silencing sequences had a 31 
nucleotide extension added to the 5’-end of the sense strand as well as base 
modifications (2’ o-methyl C, 2’ fluoro G, 2’ fluoro A, and phosphorothiolate 
bonds) to enhance stability against nuclease digestion and minimize 
immunogenicity.  The final molecular ratio of siRNA to 3DNA was 18:1. The 
siHuR (mouse) sense sequence is: 5’- GCCUGUUCAGCAGCAUUGGdTdT-3’; 
the siHuR(human) sense sequence is: 5’-
GCGUUUAUCCGGUUUGACAdTdT-3’.  
Administration to mice. For efficacy and life span studies, 3DNA formulations 
were administered in a blinded fashion to mice bearing ID8-Fluc tumors by i.p. 
injection (biw X 4) (100 µl; 3 µg ds siHuR/injection). Mice were optically 
imaged once a week. Four criteria defined life span endpoints: 1) >20% body 
weight loss from the pre-treatment weight; 2) ascites development; 3) physical 
signs of distress; 4) unknown death.   
For biodistribution analysis, mice were administered FA-3DNA-Cy3 (i.v. 
injection, 100 µl) and sacrificed 24 hrs later. Multiple tissues were collected, 
fixed and processed for paraffin sectioning. Sections were examined for 
fluorescence and representative fields were photographed using a Nikon E800 
Eclipse microscope equipped with Image Pro Plus Software and Evolution 
Camera.  
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All procedures performed on mice in this study were done in accordance with 
protocols approved by the Lankenau Institutional Animal Care and Use 
Committee. 
 
4.3.8 Apoptosis 
       Apoptotic cells were identified by terminal deoxynucleotide transferase 
dUTP nick end labeling (TUNEL) assay using an In Situ Detection Kit (Roche 
Boehringer Mannheim) as previously described [217]. 
 
4.3.9 Gene Expression Analysis 
       To identify cancer-related transcripts that were differentially expressed 
between A2780 cells transfected with siHuR or control siRNA, 200 ng of total 
RNA for each sample, isolated using a RNeasy Mini Kit (Qiagen), was analyzed 
with nCounter® GX Human Cancer Reference Kit (NanoString Technologies). 
Negative control probes were used to determine genes reliably detected. 
Statistically significant differences in gene expression were determined using 
Student’s T test (p < 0.05). Principal component analysis (PCA) was performed 
using the top 4 components, which accounted for >99% of the variance. Genes 
found to contain at least one ARE site in previous PARalyzer analysis of four 
HEK293 cell PAR-CLIP libraries were used to identify HuR targets [89]. All 
analyses were performed in R using FactoMineR for the PCA, pHeatmap for 
hierarchical clustering, and heatmap analysis and ggplot2 for the scatterplots.   
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4.3.10 Statistics 
       Survival distributions were estimated using the Kaplan-Meier method, 
and treatment groups were compared using the log-rank test. Pairwise 
comparison adjustments were made using the Dunnett-Hsu method. Statistical 
significance of differences in tumor growth rates were determined by a 
multivariate repeated measures ANOVA and differences in tumor mass were 
determined using Student’s T test. Analysis was performed using SAS 9.2 or 
later. 
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4.4 Results 
4.4.1 Elevated HuR expression in ovarian tumor cell lines and tissues 
       To date, studies in ovarian cancer have shown that cytoplasmic HuR 
accumulation correlates with poor disease progression, HuR expression is high 
across different grades of ovarian cancer, and strong nuclear HuR staining is 
often found in high grade ovarian carcinoma [169, 176].  Few comparisons of 
HuR expression in normal ovary and ovarian tumors have been made (12). Here, 
we analyzed and compared HuR expression levels between ovarian cancer and 
primary cell lines as well as between 5 normal ovaries and 31 serous ovarian 
tumors. In a Western blot analysis, we found that all ovarian cancer cells tested 
(A2780, OVCAR3, OVCAR5, and OVCA420) express higher levels of HuR (2-
6 fold) compared to ovarian primary cells (HIO80 and HIO120) (Fig. 1A).  
Immunostaining human ovarian tumors for HuR revealed cytoplasmic HuR 
expression in 29/31 tumors. Nuclear expression was high in the same 29 tumors 
(two tumors had no nuclear and cytoplasmic HuR expression). In contrast, 
normal ovary specimens had low nuclear HuR expression relative to tumors and 
no cytoplasmic HuR (Fig. 1B), in agreement with Denkert et al’s observations of 
HuR expression and localization in three normal ovaries (12).  These results 
suggest that HuR may be a good therapeutic target for the treatment of ovarian 
cancer. 
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4.4.2 In vitro suppression of HuR expression reduces ovarian cancer cell 
growth. 
In order to study the effect of HuR on ovarian cancer cell growth, we 
took three approaches to knock down HuR expression in vitro, each targeting a 
different location in the HuR coding sequence: transient transfection of small 
interfering RNA (siHuR) or stable expression (inducible and constitutive) of 
short hairpin RNAs (shHuR) (see Fig. 2 for targeted HuR sequences). First, we 
directly transfected A2780 ovarian cancer cells with siHuR615. HuR 
suppression was confirmed by Western blot and immunostaining (Fig. 3A). HuR 
mRNA was significantly reduced as well in siHuR transfected cells (Fig. 4A). 
We assessed cell viability at 24h, 48h, and 72h using a Cell Count EZ Kit to 
measure the oxidative pentose phosphate cycle (OPPC). HuR inhibition resulted 
in a 32% reduction in viable cells 72h after transfection as compared to cells 
transfected with control siRNA (p<0.05) (Fig. 3A).  
To further investigate HuR’s function in cell proliferation, we utilized a 
lentiviral gene transduction system to generate ovarian cell lines that stably 
express short hairpin RNAs (shRNAs) targeting HuR mRNA. First, we 
generated A2780 and OVCAR5 cell lines that stably and constitutively express 
either shHuRc or shCtrl. HuR protein expression was effectively silenced in a 
sustained way in shHuRc-expressing cells, whereas HuR expression remains at 
the parental cell level in shCtrl-expressing cells in both early and later passages 
(Fig. 3B and Fig. 5). HuR mRNA levels were also reduced 7-fold in shHuRc-
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expressing cells (p<0.0005) (Fig. 4B). The number of A2780 and OVCAR5 
cells was decreased 19% and 39% (compared to parental lines), respectively, in 
shHuRc-expressing cells when assayed at 72 hours after cells were plated 
(p<0.05) (Fig. 3B).  
We also generated two OVCAR3 cell lines that stably express two 
distinct doxycycline (DOX)-inducible HuR-targeted shRNAs, shHuRi289 and 
shHuRi699. We detected a 25% and 7% decrease in cell number of OVCAR3-
shHuRi289 and OVCAR3-shHuRi699, respectively, at 120 hours after DOX 
treatment (Fig. 3C). Significant suppression of HuR protein and mRNA was 
detected in both cell lines in response to DOX treatment (Fig. 3C and Fig. 6A). 
mRNA knockdown was 53% and 67% in OVCAR3-shHuRi289 and OVCAR3-
shHuRi699, respectively (p<0.005). Protein knockdown reached a maximum of 
36–64% in both cell lines at 5 days of DOX treatment (1µg/ml) (Fig. 3C). 
Importantly, DOX treatment by itself is not toxic and did not affect OVCAR3 
cell growth (Fig. 6B&C). Taken together, these results demonstrate that 
inhibition of endogenous HuR expression compromises the normal proliferation 
of ovarian cancer cells.  
 
4.4.3 HuR is required for anchorage-independent growth and facilitates 
invasion in ovarian cancer cells. 
 Being able to survive and grow in the absence of adherence to the 
extracellular matrix and neighboring cells is a characteristic of cancer cells. To 
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examine whether HuR is required for anchorage-independent growth of ovarian 
cancer cells, we assayed OVCAR5-shHuRc257 and control cells for soft agar 
colony formation over a 7-week period (Fig. 7A).  HuR suppression resulted in a 
58% and 42% decrease in colony number compared to parental (p<0.005) and 
shCtrl-expressing cells (p<0.05), respectively.  
        Cancer cells regulate the expression of a discreet set of genes in order to 
migrate and invade distant sites. HuR has been shown to affect cell migration 
through post-transcriptional regulation of invasion- and metastasis-related genes 
such as Snail and MMP-9. High grade serous carcinomas (type II) metastasize 
rapidly and attach to the abdominal peritoneum or omentum [218]. Here, we 
investigated whether altering HuR expression affects ovarian cancer cell 
migration and invasion. First, we performed in vitro scratch assays with 
OVCAR5-shHuRc257 cells. We observed a significant decrease in the rate at 
which OVCAR5-shHuRc257 cells migrated to “repair” the scratched surface as 
compared to OVCAR5 and OVCAR5-shCtrl cells. After 16 hr, closure of the 
scratch was complete in parental cells, while closure in siCtrl cells was nearly 
complete at 91% and closure in shHuR-expressing cells was only 38% 
(p=0.0001) (Fig. 7B).  Next, we performed Matrigel invasion assays in which 
cells were seeded in serum-free medium on transwell inserts coated with 
Matrigel and incubated for 24 hours with serum-rich medium in the bottom 
chambers serving as a chemo-attractant to promote invasion. We observed a 
significant decrease in the number of OVCAR5-shHuRc257 cells that had 
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invaded the Matrigel as compared to the number of invading parental OVCAR5 
and OVCAR5-shCtrl cells (58% and 48% decrease, respectively, p<0.05) (Fig. 
7C).  Taken together, these results demonstrate that inhibition of endogenous 
HuR expression compromises the migration and invasion capabilities of ovarian 
cancer cells.  
 
4.4.5 HuR inhibition suppresses ovarian xenograft growth. 
      We have previously shown that the lipidoid nanoparticle 98N12-5 
effectively delivered siRNA (claudin-3) in an ovarian cancer xenograft model 
[179]. In a subsequent study, we utilized the lipidoid siRNA delivery system to 
test the effect of HuR inhibition on the growth of human ovarian tumor cells in 
vivo. We generated human ovarian cancer xenografts by s.c. injection of 
OVCAR-3 cells into the hind flank of female nude mice. When tumor volumes 
reached ~100 mm3, mice were distributed into 3 treatment groups composed of 
tumors with equivalent sizes. Tumors in the test group were injected 
intratumorally with HuR siRNA, and tumors in control mice were injected with 
either Fluc siRNA or with PBS. Mice were treated twice per week for 4 weeks 
and tumor volumes were measured once a week with calipers for the duration of 
treatment. At the end of the fourth week, tumors in the siHuR treated group were 
significantly smaller compared to tumors treated with PBS (P=0.017) (Fig. 8A). 
However, tumor volumes between siHuR and siLuc treated groups was not quite 
significant (P=0.063). Reduction of HuR expression was significant, however, 
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when compared to HuR expression in siLuc- and PBS-treated tumors as 
determined by Western blot analysis of tumor lysates harvested at the end of the 
experiment (Fig. 8B).  
           To improve a better HuR inhibition and study its effect on the growth of 
human ovarian tumor cells in vivo, we injected the hind flank of female nude 
mice subcutaneously with equal numbers of either OVCAR5-shHuRc257 or 
OVCAR5-shCtrl cells. Three weeks post-injection, tumors were resected and 
photographed, and their volumes measured (Fig. 9). The mean tumor volumes 
generated from OVCAR5-shHuRc257 cells were significantly smaller than 
those from OVCAR5-shCtrl cells (118 +/- 21mm3 vs 357 +/- 63mm3; p = 0.0004) 
(Fig. 9). Western blot analysis of total cell lysates prepared from tumors showed 
a mean reduction of 73% in HuR protein in OVCAR5-shHuRc tumors as 
compared to OVCAR5-shCtrl tumors (Fig. 9). We observed very few apoptotic 
cells in both OVCAR5-shHuRc and OVCAR5-shCtrl upon TUNEL staining of 
tumor sections (Fig. 10). We also evaluated whether HuR inhibition affected 
tumor cell proliferation. Human Ki67 staining revealed large areas of Ki67- cells 
in OVCAR5-shHuRc tumors that were absent in OVCAR5-shCtrl tumors (Fig. 
10), in agreement with our observation that HuR inhibition resulted in a 
decrease in tumor cell proliferation in vitro (Fig. 3). To complement the Ki67 
staining of xenograft sections, we Ki67 stained parental, shHuRc, and shCtrl 
cells in culture. The percent Ki67+ parental cells was 1.4X higher than in 
shHuRc cells (p = 0.003) and 1.2X higher than in shCtrl cells (Fig. 11). No 
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apoptotic cells were observed upon TUNEL staining of all cell populations.  
Another study of xenografts generated from OVCA420 ovarian cancer cells 
confirmed that tumor volumes of shCtrl-expressed xenografts were much higher 
than shHuR-expressed xenografts (Fig. 12). Taken together, we conclude from 
these results that tumors in which HuR is suppressed are smaller than control 
tumors largely due to a reduction in cell proliferation rather than tumor cell 
death.  
 
4.4.6 Folic acid (FA)-derivatized 3DNA platform effectively targets siRNA 
to ovarian tumors. 
           To test the therapeutic efficacy of siHuR in a mouse ovarian tumor model, 
first we tested six mouse HuR siRNA sequences for in vitro HuR knockdown 
(Fig. 13, top chart). We transfected ID8 mouse ovarian surface epithelial cells 
with mouse siHuR #1-#6 for 72 hours, then subjected cell lysates to Western 
blot analysis. We found that sequences 1-3 achieved greater HuR knockdown 
than sequences 4-6 (Fig. 13, bottom). We selected siHuR sequence 1 [219] for 
further in vivo study. Next, we conjugated FA to 3DNA nanocarrier for in vivo 
targeted siHuR delivery to tumor cells following systemic delivery. 3DNA 
nanocarrier, developed by Genisphere, is a highly branched dendrimer built 
from interconnected monomeric subunits of DNA. The complexity of the 
dendrimer structure can be easily modified by the addition of more monomers to 
make multi-layered 3DNA (Fig. 14). So, for example, a functional 4-layered 
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3DNA nanocarrier consists of 30,000 DNA bases, is ~140 nm in diameter, and 
carries up to 324 single-stranded sequences at the ends of double-stranded arms. 
These single-stranded sequences can be hybridized to complementary 
oligonucleotide sequences conjugated to other components to impart 
functionality. These functional components can be DNA, mRNA, siRNA, 
chemotherapeutics, and targeting moieties.  Furthermore, fluorescent labels can 
be conjugated to 3DNA-conjugated oligonucleotides for tracking purposes. 
Importantly, we have successfully prepared CpG-free dendrimers in 
which there are no neighboring C and G bases. We observe an average of 34 
arms per CpG-free 2-layer dendrimer, similar to the CpG-containing 
dendrimers. Following systemic treatment of immunocompetent C57BL/6 
mice with CpG-containing and CpG-free dendrimer,  we measured serum 
levels of eight different cytokines 6 and 24 hours later. Mice treated with 
CpG-free dendrimer showed no immune response, in contrast to mice treated 
with CpG-containing dendrimer (Fig. 15). There is no apparent gross toxicity 
associated with dendrimer treatment of mice as mice treated twice a week for 7 
weeks have no change in physical appearance and maintain their appetite and 
body weight. The folate receptor has been shown to be overexpressed on the 
surface of many tumor cells, including ovarian [220]. We confirmed that ovarian 
cancer cells express higher amounts of folate receptor than do ovarian primary 
cells (Fig. 16A). In order to improve siHuR stability in serum, we made several 
modifications to nucleotide bases (Fig. 16B). Importantly, siHuR conjugated to 
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3DNA retains its ability to suppress HuR expression; inhibition of HuR 
expression following in vitro transfection of A2780 cells with FA-3DNA-siHuR 
is as effective as Lipofectamine-delivered siHuR (Fig. 16C).  
        To determine how effectively FA targets delivery of 3DNA to tumor 
cells, we systemically administered Cy3-labeled 3DNA with or without FA-
derivatization to C57BL/6J mice bearing tumors throughout the peritoneal 
cavity derived from murine ID8-Fluc cells. Twenty-four hours after 
administration, mice were sacrificed and multiple tissues and tumor nodules 
were collected for fluorescent microscopic analysis (Fig. 17).  We observed 
significant Cy3 fluorescence in ovarian tumors, lesser amount in normal ovaries 
of tumor-bearing mice, and very low amounts in brain, liver, spleen, and lung. 
No fluorescence was observed in heart and in the ovary of a non-tumor bearing 
mouse. This result supports the use of FA-derivatized 3DNA to target siHuR to 
ovarian tumor cells.  
 
4.4.7 FA-derivatized 3DNA tumor-targeted delivery of siHuR suppresses 
tumor growth and ascites formation, and increases life span in ID8-Fluc 
model 
              To test the therapeutic efficacy of FA-derivatized 3DNA delivery of 
siHuR, we used the ID8-Fluc ovarian cancer mouse model. We i.p. injected 
C57BL/6J mice with ID8-Fluc cells. Tumor load in these mice was assessed 
using optical imaging to detect and quantify luciferase bioluminescence as 
                                                                                                                                                                                              
 
 
70 
 
relative light units (RLU). Baseline optical images were obtained 4–6 weeks 
after mice were injected with cells. The total RLU per mouse for baseline 
images ranged from 5 X 105 to 1 X 106 RLU. Mice were distributed into 5 
groups having equivalent tumor loads (n=6 per group). The treatment schedule 
for these mice was 2 i.p. injections of either FA-3DNA-siHuR, 3DNA-siHuR, 
FA-3DNA-siCtrl, or 0.9% saline per week for 4 weeks (Fig. 18). Mice were 
optically imaged once a week. Representative optical images of mice in each 
group at baseline and at week 4 are shown in Fig. 18. The mean tumor loads 
from each of the five treatment groups were determined at week 1, 2, 3, and 4. 
Suppression of tumor growth, although not quite significant, was observed only 
in mice treated with FA-3DNA-siHuR compared to those of the other groups 
(Fig. 18). Ascites fluid accumulation in the abdomen attenuates the 
bioluminescence emitted by tumor cells. Thus, the observed bioluminescence 
may have resulted in low assessments of tumor load in the other groups and an 
underestimate in the effectiveness of the FA-targeted siHuR treatment on the 
suppression of solid tumor growth. Strikingly, only one of 6 mice treated with 
FA-3DNA-siHuR developed ascites compared to the rest of groups in which 
67%-100% of mice developed ascites (Fig. 18). Ascites index is shown in Fig. 
19. Histopathologic analysis of multiple tissues (liver, kidney, spleen, lung, 
brain, ovaries, and heart) from three mice treated with FA-3DNA-siHuR 
revealed minimal chronic inflammation (data not shown).  
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       In a separate study, we examined whether FA-3DNA-siHuR treatment of 
mice bearing ID8-Fluc tumors prolongs life. Mice were injected twice weekly 
with the same 4 treatments as in Fig 16 for 4 weeks. The median survival of FA-
3DNA-siHuR treated mice is ~1.5X longer than either the FA-3DNA-siCtrl, or 
3DNA only treated mice (43 versus 29 days; Fig. 20). The log-rank test of 
significance across the groups has a p-value of < 0.001, indicating a significant 
difference across the four treatment groups in survival. Pairwise comparisons 
adjusted using the Dunnett-Hsu method indicate that treatment with FA-3DNA-
siCtrl is significantly different from FA-3DNA-siHuR and 3DNA (p = 0.0007 
and p = 0.0093), respectively, but not significantly different from 3DNA-siHuR 
(p = 0.305). Nevertheless, it is noteworthy that treatment with the FA-
derivatized 3DNA formulation improved both efficacy and life span outcomes 
as compared to the siHuR formulation lacking the FA conjugate. 
 
4.4.8 HuR regulates transcripts that function in multiple cellular pathways 
in ovarian cancer cells. 
      To identify genes whose expression is regulated by HuR in ovarian cancer 
cells, we used a NanoString nCounter® GX Human Cancer Reference Kit to 
interrogate 230 genes (plus 6 housekeeping genes) in total RNA from A2780 
cells 72 hours after they had been transfected with siHuR615 or with siCtrl [see 
[210] for complete list of interrogated genes]. Four biological replicates of each 
sample were analyzed using multivariate statistics. Both principal component 
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analysis (PCA) and hierarchical clustering (HCL) analysis showed that the 
transcript profile changed significantly after HuR suppression (Fig. 21A&B). 
MO plots identified transcripts having significantly different expression after 
HuR knockdown (Fig. 21C). 116 genes (50%) had significantly altered 
expression; 50 had up-regulated expression and 66 had down-regulated 
expression (Table 1). We used multiple existing PAR-CLIP datasets from 
HEK293 [89] and ribonucleoprotein immunoprecipitates (RNP-IP) from 
MiaPaca-2 cells [210] to identify those transcripts to which HuR binds directly, 
and indirect targets of HuR (i.e., downstream of direct targets). Thirty-one of 50 
(62%) up-regulated genes, and 37 of 66 (56%) down-regulated genes are direct 
targets of HuR (Fig. 21D and Table 1). Using the Database for Annotation, 
Visualization, and Integrated Discovery (DAVID) to perform a functional 
annotation enrichment analysis, we determined that HuR-regulated transcripts 
with altered expression were associated with multiple essential processes 
including cell proliferation, angiogenesis, cell cycle regulation, apoptosis, and 
DNA repair (Table 2). 
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4.5 Discussion 
This is the first study to demonstrate the therapeutic potential of 
targeting HuR for the treatment of ovarian cancer. Our previous studies in 
preclinical pancreatic cancer models [85, 97, 129, 131, 221, 222], as well as 
studies by others [64, 121, 169, 209, 212, 223, 224], provided the rationale for 
investigating HuR inhibition in ovarian tumors We first established that 
suppression of HuR expression reduces proliferation, anchorage-independent 
growth, and invasion of ovarian cancer cells in vitro. We further demonstrate 
HuR inhibition-mediated reduction in tumor growth rate, delay in ascites 
development, and extension of lifespan by nearly 1.5-fold in two different 
ovarian cancer mouse models, a xenograft model and an orthotopic model in 
which mice bear tumors throughout the peritoneum.  
We used a novel DNA dendrimer nanocarrier, 3DNA, to target delivery 
of siHuR directly to the peritoneum of mice bearing ID8-Fluc tumors. 
Derivatization of 3DNA with therapeutic payloads (e.g., siRNA, miRNA, DNA, 
small molecules), targeting moieties (e.g., antibodies, ligands), and tracking tags 
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(e.g., fluorescent markers, radionuclides) allows for versatility in the design of 
3DNAs having potential for a wide range of medical applications. The results of 
this study demonstrate that systemically administered siHuR delivered by 3DNA 
retains the ability to inhibit HuR expression and achieve desirable therapeutic 
endpoints. 
       While HuR acts as a stress-response protein in tumor cells by regulating 
the expression of multiple genes known to function in tumor cell survival, HuR 
is also expressed at low levels in normal cells and plays a vital role in these cells 
as well. HuR functions in normal cells to stabilize mRNA transcripts and 
regulate their translation. It also plays a role in polyadenylation and alternative 
spicing for selected pre-mRNA transcripts [80]. In these capacities, HuR is an 
essential protein, as evidenced by the inability of HuR knockout mice to survive 
[225] and the lethal consequences of globally induced HuR silencing in adult 
mice [226]. Making use of the versatility of the 3DNA nanocarrier, we 
conjugated the 3DNA to folic acid (FA) aiming to suppress HuR in tumor cells 
while avoiding toxicity in healthy cells. Folate receptor-α (FR) expression is 
frequently amplified on tumor cells, including ovarian tumor cells, allowing for 
preferential tumor uptake via receptor-mediated endocytosis [227]. Our 
biodistribution study demonstrated efficient tumor targeting since minimal 
fluorescence was observed in normal tissues following systemically 
administered Cy3-labeled FA-3DNA. In addition, mice showed no outward 
signs of distress and we did not observe any formulation-dependent toxicity in 
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noncancerous tissues after multiple administrations of FA-3DNA-siHuR over a 
period of several weeks. However, while 3DNA-siHuR formulations 
demonstrated significant tumor growth inhibition compared to controls in 
efficacy studies, the difference of tumor growth suppression and lifespan 
extension between mice treated with FA-targeted and those treated with non-
targeted siHuR formulations was not significant. It is noteworthy, however, that 
FA-conjugation always yielded better outcomes than non-targeted formulations, 
suggesting that FA improved tumor-targeted delivery over and above that which 
would be achieved simply by the enhanced permeability and retention (EPR) 
effect. Intratumoral heterogeneity of FR expression may be a contributing factor 
that attenuates FA-targeting effectiveness. It is important to keep in mind that 
not all ovarian tumors in patients are FR+. Screening tumors for FR expression 
can be used to identify those patients that would benefit from FA-targeted 
therapy [228].  
Treatment of ovarian tumor-bearing mice with siHuR significantly 
reduced the growth rate of tumors, but complete remission of tumors was not 
attained. While targeting HuR is an attractive therapeutic strategy because it 
leads to disruption of multiple genes in core signaling pathways, the overall 
effectiveness of a monotherapy based on HuR suppression depends on the 
amount of HuR present in tumor cells. Disparity in HuR expression and 
localization is likely to be heavily influenced by the tumor microenvironment, 
which can show significant inter- and intratumoral heterogeneity in terms of 
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blood flow, oxygenation, and nutrient supply [229]. We have shown that HuR is 
engaged under conditions of hypoglycemia and hypoxia [221]. As such, HuR 
expression and cytoplasmic localization are expected to be high in regions 
within ovarian tumors with the least amount of vascularization (i.e. greatest 
hypoxia and hypoglycemia). Silencing HuR would have little effect on cancer 
cells that have low cytoplasmic HuR expression. In addition, serous ovarian 
tumors have a very high rate of genetic instability that leads to extensive 
heterogeneity within tumors [230]. Mutation of non-HuR regulated genes may 
promote tumor progression. It is also possible that the siHuR payload was not 
delivered to all tumor cells.   
We are currently taking a realistic approach and investigating 
combination therapies in which tumor-targeted siHuR is combined with either 
another siRNA or with chemotherapeutic drugs. In particular, we are combining 
siHuR with a siRNA that silences CLDN3, a non-HuR regulated gene, thus 
targeting a pathway outside the HuR binding-ome. We have previously shown 
that siRNA inhibition of the tight junction protein claudin 3 suppresses ovarian 
tumor growth in mice [179]. We are also combining siHuR with carboplatin and 
paclitaxel, the standard-of-care drugs for first-line treatment for ovarian cancer. 
We have recently shown that silencing HuR sensitizes cells grown in culture 
against DNA damaging agents, including carboplatin and paclitaxel, due in part 
to HuR’s acute upregulation of the mitotic inhibitor kinase Wee1 [129]. Thus, in 
addition to enhancing efficacy directly as a combination therapy, HuR inhibition 
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may also combat drug resistance. The versatility of the 3DNA nanocarrier may 
make it possible to target delivery of combination therapies to tumors using a 
single 3DNA formulation. 
A similar siRNA/chemotherapy combination therapy in which a siRNA 
targeting the transmembrane protein EphA2 was combined with paclitaxel 
showed promising results in preclinical tests in ovarian tumor-bearing mice and 
has recently been approved by the FDA for use in a phase I clinical trial [184, 
208]. As in our study using siHuR as a monotherapy, despite significant 
reduction in tumor growth, complete tumor remission was not obtained with the 
siEphA2/paxlitaxel combination therapy. Interestingly, EphA2 is among the 
many genes that are post-transcriptionally regulated by HuR [231]. Given the 
numerous genes and miRNAs that have significantly altered expression in 
ovarian tumors and are either presumed or have been shown to be regulated by 
HuR, some of which are known to sensitize cells to chemotherapeutics [e.g., 
miR-200c, class III β-tubulin; see [224]], tumor-targeted HuR inhibition in 
combination with clinically relevant chemotherapeutics may yield better 
therapeutic outcomes than those we have observed with siHuR monotherapy. 
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4.6 Figures and Tables 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. HuR expression is elevated in ovarian tumor cell lines and in most ovarian 
tumors. A. Top: Western blot of whole cell lysates of ovarian tumor cell lines and non-
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tumorigenic human immortalized ovarian epithelial cells (HIO 80 and HIO 120). Bottom: 
HuR amounts normalized to amounts of GAPDH (mean +/- SD) as determined by 
scanning of three independent blots. B. Representative sections of normal human ovarian 
tissue and ovarian tumor immunostained for HuR. OSE = ovarian surface epithelium. 
White bar = 100 µm. 
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Figure 2. Location and sequences of HuR (human) inhibitory oligonucleotides. 
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Figure 3A&B. HuR inhibition suppresses ovarian tumor cell proliferation. A. Top: Western blot 
of whole cell lysates (left) and A2780 cells immunostained for HuR (right) 48h following 
transfection with siHuR or siCtrl. Bottom: Number of A2780 cells at various times following 
transfection with siHuR or siCtrl. B. Top: Western blots of A2780 and OVCAR5 whole cell 
lysates that constitutively express shHuR or shCtrl. Bottom: Number of shHuRc and shCtrl 
A2780 and OVCAR5 cells 72 hours after plating. * indicates p ≤ 0.05. NT = non-transfected; NI 
= non-infected; shHuRc = constitutively expressed shHuR; GAPDH serves as gel loading control. 
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Figure 3C. HuR inhibition suppresses ovarian tumor cell proliferation. C. Top: Western 
blots of OVCAR3 whole cell lysates from cells infected with two different doxycycline 
(Dox)-inducible shHuRs and treated for various times +/- DOX. Bottom: Number of two 
different DOX-inducible shHuR-infected OVCAR3 cells after treatment +/- DOX for 
various times. * indicates p ≤ 0.05. shHuRi = inducible shHuR; GAPDH serves as gel 
loading control. 
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Figure 4. A. HuR mRNA levels measured by RT-PCR in A2780 transiently-transfected 
with siHuR and siCtrl. B. Constitutively expressed shHuR maintains inhibition of HuR 
expression in ovarian tumor cells. Western blots of total cell lysates of parental and 
shHuR-constitutively expressing A2780, OVCAR5, and OVCA420 cells at various 
passage numbers. C. HuR mRNA levels measured by RT-PCR in late passages of A2780 
and OVCAR5 cells expressing shHuRc or shCtrl. * = p<0.0005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A2780 
A2780-shHuRc (p8) 
OVCA420 
OVCA420-shHuRc (p6) 
OVCAR5 
OVCAR5-shHuRc (p4) 
A2780-shCrtl (p2) 
OVCAR5-shCrtl (p4) OVCA420-shCrtl (p1) 
HuR 
GAPDH 
Later passages 
1 1 1 0.02 0.83 1.15 0.05 0.11 0.67 HuR/GAPDH 
A
27
80 
A
27
80
-
sh
H
u
R
c 
(p
3) 
O
V
C
A
42
0 
O
V
C
A
42
0-
sh
H
u
R
c 
(p
2) 
O
V
C
A
R
5 
O
V
C
A
R
5-
sh
H
u
R
c 
(p
1) 
Early passages 
1 0.03 1 0.01 1 0.04 
HuR 
GAPDH 
                                                                                                                                                                                              
 
 
84 
 
 
 
 
 
Figure 5. Constitutively expressed shHuR maintains inhibition of HuR 
expression in ovarian tumor cells. Western blots of total cell lysates of parental 
and shHuR-constitutively expressing A2780, OVCAR5, and OVCA420 cells at 
various passage numbers. 
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Figure 6. A. HuR mRNA levels in parental and transfected OVCAR3 cells upon shHuR 
induction with 1mg/ml DOX. PAR = parental. B. Western blots of cell lysates following 
incubation with various concentrations of doxycycline. C. OVCAR3 toxicity following 
incubation with various concentrations of doxycycline.  
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Figure 7A&B. HuR inhibition suppresses anchorage independent growth and migration 
of ovarian cancer cells. A. Anchorage independent cell growth in soft agar. Top: Images 
of iodonitrotetrazolium-stained colonies of three indicated cell lines. Bottom: mean 
number of colonies. B. In vitro scratch assays. Top: Images of in vitro scratch assays 
performed with three indicated cell lines. Images were taken at 0 and 16 hours. Bottom: 
Quantification of the rate of scratch closure, as measured by change in wound size 
relative to the 0 h time point. * indicates significant difference from shHuR-expressing 
cells. 
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Figure 7C. HuR inhibition suppresses anchorage independent growth and migration of 
ovarian cancer cells. C. Matrigel invasion assay. Top: Images of Matrigel invasion assays 
performed with three indicated cell lines. Cells that invaded through the Matrigel and 
onto the basal surface of transwell inserts were stained and photographed at 10X 
magnification. Bottom: Quantification of Matrigel invasion assays. Values for each cell 
line were normalized to the number of cells in the untreated condition. * indicates 
significant difference from shHuR-expressing cells. 
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Figure 8. HuR siRNA treatment of OVCAR-3 xenografts. A. Fold increase in tumor 
volume compared with baseline tumor volume at the 4th week. Each point represents a 
single tumor. The mean tumor volume at each time point is designated by a horizontal 
line. B. Western blot analysis of HuR protein in OVCAR-3 xenografts injected with HuR 
siRNA, Fluc siRNA, or PBS.  
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Figure 9. Xenografts in athymic nu/nu mice from OVCAR5 cells infected with shHuRc 
or shCtrl constructs. Top left: Photograph of tumors dissected from mice. Bottom left: 
Western blot of protein lysates from OVCAR5-shCtrl and OVCAR5-shHuRc xenografts. 
GAPDH serves as gel loading control. Right: Tumor volumes measured three weeks after 
cell implantation. 
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Figure 10. TUNEL and Ki67 staining for detection of proliferating and apoptotic cells, 
respectively. TUNEL and Ki67 stained sections of four OVCAR5-shHuR and four 
OVCAR5-shCtrl ovarian xenografts. Areas of Ki67
-
 cells are delineated with a white 
dotted line.       
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Figure 11. TUNEL and Ki67 staining for detection of proliferating and apoptotic cells, 
respectively. In vitro staining of parental OVCAR5 cells, OVCAR5-shCtrl cells and 
OVCAR5-shHuR cells. Ki67
+
 cells and DAPI-stained cells were counted in three 1.4mm
2
 
fields to determine % Ki67
+
 cells. * indicates p = 0.003 between parental and shHuR 
cells. DAPI stains nuclei in panels A and B. White bar = 50 mm.  
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Figure 12. Photograph of athymic nu/nu mice bearing OVCA420-shCtrl (left) and 
OVA420-shHuR (right) xenografts. Red arrows point the locations of tumors.  
 
 
 
 
 
 
 
 
Duplex ID Parental Sense Sequence (5'-3') Parental Antisense Sequence (5'-3') 
mouse 
siHuR1 GCCUGUUCAGCAGCAUUGGTT CCAAUGCUGCUGAACAGGCTTTTTTTTTTTTTTTTTTTT 
mouse 
siHuR2 UGGCGAGGUUGAAUCUGCATT UGCAGAUUCAACCUCGCCATTTTTTTTTTTTTTTTTTTT 
mouse 
siHuR3 UUUCUCGGUUUGGGCGAAUTT AUUCGCCCAAACCGAGAAATTTTTTTTTTTTTTTTTTTT 
mouse 
siHuR4 AGGCUAGUAUUUAGUUCUUTT AAGAACUAAAUACUAGCCUTTTTTTTTTTTTTTTTTTTT 
mouse 
siHuR5 AGGUAAUGUUCAUUCAUCATT UGAUGAAUGAACAUUACCUTTTTTTTTTTTTTTTTTTTT 
mouse 
siHuR6 AGCUCUUCAAAGUCGUAUUTT AAUACGACUUUGAAGAGCUTTTTTTTTTTTTTTTTTTTT 
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Figure 13. Top: Table of 6 mouse siRNA sequences against HuR. Bottom: 
Western blots of total cell lysates of transfected with mouse siRNAs (#1-6) and 
non-transfected (NI).  
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Figure 14.   3DNA
®
 dendrimer platform for in vivo tumor-targeted delivery of siHuR. 
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Figure 15. Immune response to CpG-containing and CpG-free DNA dendrimers. Blood 
serum was collected 6 hr and 24 hr after i.v. administration of dendrimers or PBS to 
C57BL/6 mice. Cytokines measured using a Th1/Th2 BioPlex detection kit (BioRad). 
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Figure 16. A. Ovarian cancer cell lines, non-tumorigenic human immortalized ovarian 
epithelial cells (HIO 80 and HIO 120), and murine ID8-Fluc cells express the folate 
receptor.  B. Serum stability. siHuR incubated for 1 hr at 37
o
C, then assayed on a 
10%Tris/Borate/Urea PAGE. Sense strand: 42 bases (modified bases + extension); 
Antisense strand: 22 bases (modified bases).  C. In vitro siHuR knockdown activity. 
siHuR (13nM) was combined with lipofectamine or targeted 3DNA dendrimer and 
incubated with A2780 cells overnight in 10% serum-containing medium. Dendrimer plus 
a scrambled siHuR had no knockdown activity (not shown).  
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Figure 17. Biodistribution of Cy3-conjugated 3DNA +/- conjugation to folic acid (FA). 
Following systemic delivery of FA-targeted Cy3-3DNA to ovarian tumor bearing mice, 
significant Cy3 fluorescence was observed in ovarian tumors, lesser amount in normal 
ovaries of tumor-bearing mice, very low amounts in brain, liver, spleen, and lung (white 
arrows), and no fluorescence was observed in heart. No fluorescence was observed in the 
ovary of non-tumor bearing mouse. 
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Figure 18. Systemic treatment with FA-3DNA-siHuR of mice bearing ID8-luc 
ovarian tumors suppresses tumor growth and extends life span. A. Treatment 
schedule is shown at the top. Tumor load was assessed weekly by optical 
imaging (typical images are shown). Weights of mice during the treatment 
period are indicated at the top of the graph. The incidence of ascites 
development in different treatment groups is indicated on the right. Upper right: 
Western blot of ID8-luc cell lysates following 48 hr treatment +/- siHuR.  
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Figure 19. Representative mice having different degrees of ascites development.   
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Figure 20. Systemic treatment with FA-3DNA-siHuR of mice bearing ID8-luc 
ovarian tumors suppresses tumor growth and extends life span. B. Kaplan-Meier 
survival curve of mice bearing ID8-FLuc cells injected i.p. twice weekly with 
either FA-3DNA-siHuR, 3DNA-siHuR, FA-3DNA-siCtrl, or 3DNA 
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Figure 21.  A. Principal component analysis (PCA), and B. Hierarchical Clustering (HCL) 
Analysis showing distinct difference between transcript profiles of siCtrl- and siHuR-
transfected A2780 cells. C and D. MA plots of gene expression of 163 genes following 
transfection of A2780 cells with siHuR and with siCtrl. C. 66 genes were significantly 
down-regulated and 50 genes were significantly up-regulated when HuR was knocked 
down. D. 37 significantly down-regulated genes (56%) are direct HuR targets (i.e., HuR 
binds to their mRNA transcript); 31 significantly up-regulated genes (62%) are direct 
HuR targets.       
 
Table 1. HuR-regulated transcripts in A2780 cells. Shaded boxes indicate 
transcripts to which HuR binds directly.  
                                                                                                                                                                                              
 
 
102 
 
 
       
                                                                                                                                                                                              
 
 
103 
 
Table 2. Biological function of 5 up-regulated and 6 down-regulated genes 
having the highest fold differences in expression in response to HuR inhibition 
in A2780 cells. Shaded boxes indicate transcripts to which HuR binds directly. 
 
 
Up-regulated 
upon 
HuR knockdown 
 
Fold change 
 
Biological function 
DAP3 5.94 Apoptosis 
IFNGR1 4.89 Interferon-g signaling pathway 
BRAF 3.26 Signal transduction 
CXCL9 2.59 Chemokine signaling pathway 
ATM 2.46 Cell cycle control; p53 signaling pathway 
Down-regulated 
upon 
HuR knockdown 
 
Fold change 
 
Biological function 
CSF1R 0.16 Cytokine-cytokine receptor interaction 
PTPN11 0.23 Angiogenesis; Interferon-g signaling pathway 
XRCC5 0.26 DNA repair 
WNT10B 0.30 Wnt signaling pathway 
RARA 0.33 Transcription regulation 
COL1A1 0.33 Integrin signaling pathway 
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       Chapter 5 
Insights from HuR Biology Point to Potential Improvement for Second-
Line Ovarian Cancer Therapy  
 
       5.1 Abstract 
This retrospective study aimed to investigate the role that an RNA-
binding protein, HuR, plays in the response of high grade serous ovarian tumors 
to chemotherapeutics. Surgically-debulked ovarian tumor sections were 
immunohistochemically stained for HuR and the degree of cytoplasmic staining 
was scored. Data was statistically evaluated to assess whether a correlation 
exists between HuR intracellular localization and progression free survival (PFS) 
following second-line therapy. Ribonucleoprotein immunoprecipitation (RNP-IP) 
was performed on ovarian cancer cells in culture to determine if HuR regulates 
deoxycytidine kinase (dCK), a metabolic enzyme that activates gemcitabine. 
The effects of carboplatin treatment on expression of HuR and the mitotic 
inhibitor WEE1, and on cell cycle kinetics, were also examined. We found no 
correlation between cytoplasmic HuR amount in tumor cells and PFS.  HuR 
post-transcriptionally regulates dCK mRNA in ovarian cancer cells. Treatment 
of ovarian cancer cells with carboplatin results in increased HuR cytoplasmic 
expression and elevated WEE1 expression, arresting cell cycle G2/M transition. 
This may explain why HuR cytoplasmic localization is not predictive of 
therapeutic response to combination gemcitabine/carboplatin therapy and PFS. 
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These results suggest combination treatment of recurrent ovarian tumors with 
gemcitabine, carboplatin, and a WEE1 inhibitor may be potentially 
advantageous as compared to current clinical practices. 
 
       5.2 Introduction 
   Nearly 80% of ovarian cancer patients will have a favorable response 
to first-line therapy consisting of optimal surgical debulking followed by 
aggressive chemotherapy with paclitaxel and a platinum-based therapy [232]. 
Unfortunately, due to the development of chemoresistant disease, a majority of 
patients will develop recurrent tumors within 16-22 months. Gemcitabine in 
combination with carboplatin is commonly used as a second-line chemotherapy 
to treat recurrent disease. Some tumors respond better to a combination of 
gemcitabine and carboplatin than others, resulting in longer progression free 
survival (PFS).  Unfortunately, the field does not have a reliable biomarker to 
determine which patients will respond well. Even when patients respond to the 
most aggressive therapy, almost all will eventually succumb to their disease.  
  Gemcitabine acts as a prodrug that, when metabolized to gemcitabine 
di- and tri-phosphates, functions to inhibit DNA elongation, DNA repair 
enzymes, and RNA synthesis [233, 234]. Potential clinical relevance of an 
association between the amount of cytoplasmic localization of an RNA-binding 
protein, HuR, in tumor cells and the metabolic activation of gemcitabine has 
recently been identified [85, 97]. HuR functions in normal, healthy cells as a 
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critical molecule involved in post-transcriptional gene regulation. When cells are 
stressed, e.g., by low oxygen levels, HuR potently influences translation of key 
survival and growth-related mRNAs in the cytoplasm by several mechanisms 
including active transport of mRNAs from the nucleus to the cytoplasm, mRNA 
stabilization, and direct facilitation of translation. HuR’s role in the stress 
response is most likely part of a survival mechanism used by the most 
aggressive cancer cells in a tumor. In line with these functions, HuR has been 
identified as a marker for poor prognosis in many cancers, including ovarian 
cancer [207, 235, 236]. Two studies have shown that high cytoplasmic 
expression of HuR in pancreatic ductal adenocarcinoma cells in culture 
dramatically sensitizes cells to gemcitabine [85, 97]. In addition, in small 
cohorts of pancreatic cancer patients treated with gemcitabine following surgery, 
a significant association between increased overall survival and high HuR 
expression in the cytoplasm has been identified, suggesting that HuR subcellular 
localization might serve as a predictive marker for gemcitabine response [85, 
97]. Enhanced gemcitabine functionality in tumors is likely the consequence of 
increased production of the key nucleoside analog metabolizing enzyme, 
deoxycytidine kinase (dCK) resulting from post-transcriptional regulation of 
dCK mRNA by HuR [85, 97, 199, 200]. In this study, we sought, but found no 
evidence, that HuR cellular localization might serve as a predictive marker for 
clinical outcome following gemcitabine treatment of recurrent ovarian tumors. 
We explored potential reasons why this might be the case. The results of our 
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findings suggest that improved clinical outcomes for ovarian cancer patients 
might be better achieved using gemcitabine in combination with carboplatin and 
a WEE1 inhibitor as a second-line therapy.  
 
 
       5.3 Materials and Methods 
5.3.1 Patient population. Medical records from our gynecologic oncology 
practice (CJD) at the Lankenau Medical Center, Wynnewood, PA, were 
reviewed to identify ovarian cancer patients who had undergone surgical 
debulking and first-line treatment with carboplatin and paclitaxel, who 
subsequently developed recurrent tumors and underwent further therapy with 
gemcitabine in combination with carboplatin (26/31) or other chemotherapeutic 
(3/31). Using patients’ medical record numbers to assure sample de-
identification, archival paraffin blocks of tumor tissue from 31 patients were 
retrieved and sections were prepared. This protocol was approved by the 
Lankenau Medical Center Institutional Review Board. The patient profile is 
summarized in Supplemental Table 1. Progression free survival time was 
determined by CA125 Resist based on serial CA125 measurements, as well as 
on CT scans. 
 
5.3.2 Generation of HuR knock-down cell lines. HuR stable knock-down cell 
lines were generated in our lab as previously described [98]. Briefly, to generate 
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OVCAR5 cells stably-expressing shHuRc257 (“c” for constitutive) or shCtrl, 
cells were infected with shHuRc257- or shCtrl-expressing lentivirus. Twenty-
four hours after viral infection, shHuRc257- or shCtrl-expressing cells were 
selected in medium containing hygromycin B (Gemini #400-123). To generate 
OVCAR3 Dox-inducible shHuRi699 cells (“i” for inducible), cells were infected 
with shHuRi699-expressing lentivirus. Forty-eight hours post-viral infection, 
shHuR- or shCtrl-expressing cells were selected in medium containing 
puromycin dihydrochloride (Gemini # 400-128P). 
 
5.3.3 Cell Culture, transfection, chemo-treatment, and viability assay. 
OVCAR5 cells (A. Klein-Szanto, Fox Chase Cancer Center) and A2780 cells (T. 
Hamilton, Fox Chase Cancer Center) were maintained in RPMI-1640 medium 
(Cellgro) supplemented with 10% FBS (Gemini) at 37°C in 5% CO2. OVCAR3 
cells were purchased from American Type Culture Collection (ATCC) and 
grown in media as recommended by ATCC. All cells tested negative for 
mycoplasma using a PCR kit (Sigma #MP0035-1KT). For in vitro transfection, 
cells were transiently transfected with siDCK (Ambion #4390824) or siControl 
(Ambion #AM4611) using Lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s directions. To determine effects of gemcitabine on HuR and 
dCK expression, or carboplatin on HuR and WEE1 expression, cells were 
incubated in IC50 concentrations of gemcitabine (0.02 μM) or in carboplatin 
(7.5 μM) for various times, then harvested for Western blot analysis. To 
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determine effects of gemcitabine on HuR knockdown cell proliferation, 
OVCAR5-shHuRc257 cells were incubated with various concentrations of 
gemcitabine for 72 hours and OVCAR3-shHuRi699 cells were incubated with 
1µg/ml doxycycline and various concentrations of gemcitabine for 72 hours, 
after which viable cell number was determined using EZ Count Kit (Rockland 
#KLD-001). All cell viability assays were done in triplicate. 
 
5.3.4 Immunoblot analysis. To prepare whole cell extracts, cells were 
homogenized in RIPA buffer containing proteinase inhibitors and centrifuged at 
12,000 rpm for 15 min at 4oC.  Cytoplasmic and nuclear cell extracts were 
prepared [Nuclear and Cytoplasmic Extraction kit (Pierce #78833)] and protein 
concentration of extracts was determined [BCA Protein Assay Kit (Pierce 
#23225)]. Soluble proteins were separated on 10% SDS-PAGE gels and 
analyzed by Western blotting using antibodies toHuR (1:1000) (clone 3A2; 
Santa Cruz Biotechnology), dCK (1:500) (clone 2243C2; Santa Cruz), WEE1 
(1:1000) (clone B11; Santa Cruz), lamin A/C (1:1000) (clone 636; Santa Cruz 
Biotechnology), or GAPDH (1:8000) (clone 5C6; Ambion).  Blots were washed 
several times with PBST (phosphate buffered saline, 0.1% Tween), then 
incubated with horseradish peroxidase-labeled goat anti-mouse (1:8000) 
(Thermo Scientific) secondary antibody. Proteins were visualized with ECL 
(Pierce #32106). Densitometry quantification of proteins was done using Image 
J software.  
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5.3.5 Immunostaining. Antigen retrieval was performed on deparaffinized 
tumor sections by steam heating for 30 min in citrate buffer followed by 
endogenous peroxidase quenching with 3% H2O2/methanol for 20 min. Cells 
were grown in chamber slides, then fixed in cold acetone at -20oC for 10 
minutes. Tumor sections or cells were incubated with primary antibody 
and biotinylated secondary antibody. Signals were amplified and visualized 
either using the TSA-Plus Fluorescence System (Perkin Elmer) according to 
manufacturer’s instructions, or using avidin/biotin complex system 
(VECTASTAIN Elite ABC kit from VECTOR Laboratories) followed by DAB 
visualization and hematoxylin counterstaining. Slides were imaged with a Zeiss 
Axiovert 200M microscope or Zeiss Axioplan microscope. Human ovarian 
tumor HuR cytoplasmic staining was scored as -, +/-, ++, or +++. Stained 
sections were viewed and scored twice by two different pairs of investigators 
(JAS and WP; JAS and GSD) who were blind to PFS of each patient. Anti-HuR 
monoclonal antibody 19F12 (1:5000) was from Clonegene. Anti-dCK (Abcam 
#ab151966) was from Abcam. Anti-WEE1 (clone B-11) was from Santa Cruz. 
 
5.4.6 Ribonucleoprotein-immunoprecipitation (RNP-IP). RNP-IPs were 
performed as described [237].  Briefly, A2780 or OVCAR3 cells were treated 
with 1µg/ml gemcitabine for 12 hours, then cytoplasmic lysates were obtained 
using CelLytic NuCLEAR Extraction Kit (Sigma-Aldrich, #NXTRACT) 
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according to manufacturer’s instructions, with the modification of 
supplementing with 100 U/ml RNase inhibitor (Life Technologies, # N8080119) 
to preserve RNA integrity.  HuR protein and its bound mRNA cargo were 
immunoprecipitated by incubating the cytoplasmic lysates with mRNP-IP-grade 
HuR antibody (MBL International Corp. #RN004P) or isotype control IgG 
(Santa Cruz #sc-2027) pre-coated to Protein A-Sepharose beads (Sigma-Aldrich 
#P9424).  HuR was digested with proteinase K (Life Technologies, cat. 
#AM2546). After IP, the RNA was isolated and cDNA synthesized (A&B 
applied biosystems #4368814). GAPDH and dCK transcripts were quantified by 
real-time PCR analysis (#4352024) using specific probes, dCK 
(#Hs01040726_m), 18S (#Hs99999901_s1), and SUMO-1(#Hs02339312_g1) 
(A&B Applied Biosystems). The relative levels of dCK product were first 
normalized to 18S product in all IP samples, then fold changes in HuR-IP were 
compared with IgG-IP.  
Statistical analysis. The distribution of PFS was estimated using the Kaplan-
Meier method and association of HuR expression with PFS was assessed using 
the log-rank test. Correlations of tumor grade with HuR expression, HuR and 
dCK expression, and HuR and WEE1 expression were evaluated using Fisher’s 
exact test. 
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5.4 Results 
5.4.1 Is HuR cellular localization in ovarian tumors predictive of favorable 
tumor response to gemcitabine? 
              We investigated whether there is a correlation between subcellular 
localization of HuR in tumor cells and PFS of ovarian cancer patients receiving 
gemcitabine as a second-line therapy for recurrent tumors. Sections of thirty-one 
ovarian tumor specimens from patients treated with gemcitabine were 
immunostained for HuR. Twenty-nine of the specimens were from chemo-naive 
tumors (i.e., surgically-debulked tumors prior to any chemotherapy), while two 
were from secondary surgically- debulked tumors following first-line 
chemotherapy with carboplatin and paclitaxel (Figure 1A). Twenty-nine of the 
31 tumor specimens were from patients receiving second-line therapy with 
gemcitabine in combination with one or more chemotherapeutics – 26 with 
carboplatin, 1 with carboplatin and avastin, and 2 with cisplatin (Table 1). Two 
of the 31 tumors had HuR expression in only a few nuclei and no cytoplasmic 
HuR, 1/30 had only nuclear staining, while HuR was present in at least 50% of 
nuclei and in the cytoplasm of 28/30 tumors. The amount of cytoplasmic HuR in 
these 28 tumors varied: 7 were scored +/-, 9 were +, 6 were ++, and 6 were +++ 
(Figure 1B). To assess whether the amount of cytoplasmic HuR expression in 
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tumors was predictive of PFS following gemcitabine/carboplatin, we compared 
PFS of patients whose tumors had low cytoplasmic HuR expression (-, +/-, +; 
n=19; median = 8 mo) with that of patients whose tumors had high cytoplasmic 
HuR expression (++ and +++; n=12; median = 8 mo) (Figure 1C). There was no 
significant difference in PFS (p=0.58). Even when tumors that were scored as + 
were grouped with ++ and +++ tumors, there was no significant difference in 
PFS (- and +/-; n=9; median = 8 mo) and (+, ++, +++; n=22; median = 8 mo) 
(p=0.62). The two tumor specimens that were collected after first-line therapy 
had cytoplasmic HuR scores of + and +++, and had PFS values of 3 mo and 4 
mo, respectively. The PFS of the 3 patients whose tumors had no detectable 
HuR in the cytoplasm was near or above the median value (8 mo, 8 mo, 12 mo). 
These data provide no evidence to support the use of HuR cellular localization 
as a predictive marker for ovarian tumor sensitivity to second line treatment with 
gemcitabine. We note, however, a correlation of lower tumor grades (Grades I 
and II) with low cytoplasmic HuR, and Grade III tumors with high cytoplasmic 
HuR approached significance (p=0.066) (Table 2). 
Patients in this study were treated with different numbers of cycles of 
carboplatin/paclitaxel (1X, n=18; 2X, n=7; 3X, n=2; 4X, n=3; 5X, n=5), thereby 
contributing variability to the duration of first-line carboplatin/paclitaxel therapy 
and the time between assessment of HuR localization status in surgically-
debulked tumors and the initiation of gemcitabine treatment. In addition, 
patients were treated with different numbers of cycles of gemcitabine as second-
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line therapy (range 2-11), with most patients treated 5 (n=8) or 6 (n=11) times, 
and with gemcitabine in combination with different chemotherapeutic drugs. 
These variables may contribute to our failure to identify a correlation between 
HuR cellular localization in ovarian tumors and PFS as was observed in 
pancreatic adenocarcinoma where gemcitabine is administered to patients as a 
first-line therapy.  We investigated possible molecular mechanisms that might 
be operative in the context of these variables.  
 
5.4.2 dCK activates gemcitabine in ovarian cancer cells. 
             In nucleotide metabolism, deoxycytidine kinase (dCK) is the rate 
limiting enzyme that phosphorylates deoxyribonucleosides as well as their 
nucleoside analogs (e.g., gemcitabine) [238]. To confirm that dCK activates 
gemcitabine in ovarian cancer cells, thereby mediating its cytotoxic effect as has 
been demonstrated in pancreatic cancer cells [238], we transiently transfected 
A2780 cells with siRNA against dCK (siDCK) or siControl (siCtrl) for 24 h, 
then treated cells with various concentrations of gemcitabine for 48 h and 
measured viable cells. In parallel cultures, we confirmed dCK suppression in 
siDCK-transfected cells by western blot analysis (Figure 2). dCK inhibition 
resulted in ~80% increase in cell number when cells were treated with 0.005 and 
0.01 μM gemcitabine as compared to gemcitabine-treated siCtrl-transfected and 
untransfected cells (p<0.005) (Figure 2). These results support gemcitabine 
activation by dCK in ovarian cancer cells. 
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5.4.3 dCK mRNA is a target of HuR in ovarian cancer cells. 
             Binding of HuR protein to specific target mRNA transcripts is a highly 
regulated process subject to modifications of HuR protein itself (e.g., 
phosphorylation and methylation) as well as competition with miRNAs for 
binding sites [104, 106, 107, 111, 239]. We have shown that HuR, in response to 
gemcitabine treatment, binds to dCK mRNA in pancreatic tumor cells resulting 
in increased dCK protein expression and activity [85]. Our recent studies 
identified HuR mRNA targets in ovarian and pancreatic cancer cells that are 
unique to these two cancer types [98, 240]. It is therefore possible that HuR may 
not directly associate with dCK mRNA in ovarian cancer cells as it does in 
pancreatic cancer cells, thereby offering a possible explanation why HuR 
cytoplasmic localization failed to serve as an informative marker for 
gemcitabine sensitivity. To test whether HuR translocation from the nucleus to 
the cytoplasm in response to gemcitabine correlates with an increase in dCK 
expression in ovarian cancer cells, we treated OVCAR5 cells with 0.02 µM 
gemcitabine (IC50) (Figure 3), prepared cytoplasmic and nuclear protein 
fractions at various time points, and analyzed the amount of HuR and dCK 
proteins in these two cellular compartments on western blots. Cytoplasmic HuR 
and dCK levels peaked between 16 h and 48 h after gemcitabine treatment 
(~1.5-fold higher than level at 0 h) (Figure 4). An increase in dCK mRNA was 
also observed by qRT-PCR during this timeframe (Figure 5A). Increased 
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cytoplasmic HuR at 48 h after gemcitabine treatment was also observed by 
immunofluorescent staining (Figure 5B). The amount of nuclear HuR, however, 
appeared unchanged upon gemcitabine treatment (Figure 4), most likely due to 
masking of subtle changes in its abundance that are not detected on western 
blots. The same analysis of another ovarian cancer cell line, A2780, confirmed 
the association of gemcitabine-induced elevation of cytoplasmic HuR and dCK 
mRNA/protein (Figure 6). Sections of human ovarian tumors immunostained for 
HuR and dCK revealed a positive correlation (p=0.008) between cytoplasmic 
HuR expression and dCK expression (Figure 7). These results show that 
gemcitabine treatment induces HuR translocation to the cytoplasm and that this 
translocation is associated with increased dCK expression in ovarian cancer cells. 
          The dCK 3’UTR region contains 8 putative HuR recognition motifs 
[84].  To determine whether HuR binds directly to dCK mRNA in ovarian 
cancer cells, we performed RNP-IP assays on lysates prepared from A2780 cells 
grown in the presence or absence of gemcitabine for 12 hours. An RNP-IP with 
a HuR-specific antibody was performed to isolate total mRNA transcripts 
associated with HuR, followed by qRT-PCR to determine the amount of dCK 
mRNA associated with HuR protein. IgG RNP-IP was performed as a negative 
control (Figure 8). The dCK mRNA level was increased 4-fold in gemcitabine-
treated cells compared to untreated cells. SUMO-1 mRNA, a HuR target 
(unpublished, Brody Lab), served as a positive control and was enriched ~2 fold 
upon gemcitabine stress (Figure 8A). The same study performed in OVCAR3 
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cells confirmed the observation that mRNAs isolated from HuR RNP-IP 
samples were significantly enriched in dCK mRNA transcripts (Figure 9). These 
results indicate that HuR binds directly to dCK mRNA in ovarian cancer cells, 
just as it does in pancreatic cancer cells.    
 
5.4.4 HuR suppression reduces dCK expression and gemcitabine efficacy 
           To study HuR regulation of dCK further, we examined the effect of 
HuR silencing on dCK expression. We generated an ovarian cancer cell line, 
OVCAR5-shHuRc257 that stably expresses short hairpin RNA (shHuR) [98]. 
We stressed OVCAR5, OVCAR5-shCtrl, and OVCAR5-shHuRc257 cells with 
0.02 µM gemcitabine for 0, 6, 12, 24, 48, and 72 h then prepared whole cell 
lysates to measure dCK expression on western blots (Figure 10). dCK protein 
expression in gemcitabine-treated OVCAR5 and OVCAR5-shCtrl cells 
increased (35-84%) in a time dependent manner (Figure 10). In comparison, 
dCK expression in gemcitabine-treated OVCAR5-shHuRc257 cells remained 
unchanged at all time points except at 72 h when a minor increase was observed 
(Figure 10). A small increase in total HuR expression was observed in 
gemcitabine-treated OVCAR5-shHuRc257 cells. This observation likely reflects 
previous reports of HuR self-regulation [101, 147, 241].  
         To further demonstrate HuR binds to and stabilizes dCK mRNA, we 
cloned dCK3’UTR (sequence shown in Figure 11) into 3’-end of Renilla 
Luciferase gene of a dual Luciferase reporter system, psiCheck-1 (Fig. 12A). 
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We transfected OVCAR5-shCtrl and –shHuR cells with vector or RLuc-3’UTR 
plasmids for 24 h, then treated transfected cells with or without 0.02 µM 
gemcitabine for another 48 h. The ratio of Renilla luciferase and Fire-fly 
luciferase activities in gemcitabine-treated cells was measured and normalized 
to untreated cells. Fire-fly luciferase activity served as a transfection control. In 
HuR-expressing OVCAR5-shCtrl cells, RLuc-3’UTR activity is 2X higher than 
in cells transfected with RLuc only (p<0.005). In HuR-depleted OVCAR5-
shHuR cells RLuc-3’UTR activity is close to RLuc only (p=0.08) (Fig. 12B). 
This result suggests dCK3’UTR enhances RLuc activity in HuR expressing cells. 
           Next, we determined the impact of HuR inhibition on ovarian cancer cell 
sensitivity to gemcitabine. We treated two cell lines, OVCAR5-shHuRc257 and 
OVCAR3-shHuRi699, doxycycline (DOX)-inducible HuR-targeted shRNA 
ovarian cancer cell lines, with various gemcitabine concentrations for 72 h, and 
then assessed cell viability. HuR suppression in OVCAR5-shHuRc257 and 
DOX-induced OVCAR3-shHuRi699 cells compared to control cells resulted in 
less sensitivity to gemcitabine (Figure 5). In sum, these experiments show that 
HuR translocation to the cytoplasm as a stress response to gemcitabine exposure 
results in increased dCK expression.  This, in turn, results in enhanced 
gemcitabine therapeutic efficacy in ovarian cancer cells. It is clear that there 
must be another confounding factor or factors that compromise the value of HuR 
cellular localization as a predictive marker of second-line gemcitabine efficacy.  
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5.5 Discussion 
            Nearly all of the tumor samples examined in our patient study (29/31) 
were obtained from surgical debulking procedures performed prior to first-line 
carboplatin/paclitaxel treatment. Given our previous study in which we showed 
HuR translocation from the nucleus to the cytoplasm in pancreatic cells upon 
stress with DNA-damaging anticancer agents including carboplatin and 
paclitaxel (22), it is reasonable to expect an increase in cytoplasmic HuR in 
response to exposure to first-line treatment, far in advance of 
gemcitabine/carboplatin second-line therapy. The fact that 12/29 of the tumors 
had significant cytoplasmic HuR prior to first-line therapy, and the PFS of these 
patients was not significantly different from that of patients with low 
cytoplasmic HuR, is further evidence that the complexity of HuR biology 
abrogates its use as a predictive marker for efficacy of gemcitabine second-line 
therapy. Ideally, it would be preferable to determine HuR status just prior to 
gemcitabine therapy, but surgical debulking of recurrent tumors is rarely 
performed, limiting the clinical feasibility of attaining tumor specimens. 
            Another complication is that gemcitabine is nearly always administered 
to ovarian cancer patients in combination with one or more chemotherapeutics, 
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usually carboplatin. A recent study showed that DNA-damaging radiation 
therapy, given in combination with gemcitabine, may disrupt HuR’s ability to 
act as an informative biomarker (9). Expression of WEE1, a mitotic inhibitor 
kinase that regulates the DNA damage repair pathway, has been reported in 
ovarian cancer ascites following chemotherapy [242]. We have shown that 
WEE1, is an HuR target in pancreatic cancer cells [129]. Thus, overexpression 
of HuR in response to DNA-damaging chemotherapeutics (e.g., carboplatin) 
results in elevation of WEE1 protein, promoting cell-cycle arrest at the G2/M 
transition and ensuing resistance to DNA-damaging agents. To explore whether 
HuR regulation of WEE1 provides a mechanism to account for the lack of 
improved PFS associated with cytoplasmic HuR in ovarian tumors of patients 
treated with a combination of gemcitabine and carboplatin, we first assayed HuR 
expression in OVCAR5 cells treated with 7.5 µM carboplatin (IC50) for various 
times. Cytoplasmic HuR began to increase after 24 h treatment with carboplatin 
and reached a maximum increase of 1.6-fold higher than in non-treated cells at 
48 h (Figure 6A). The amount of nuclear HuR remained high in treated cells at 
all time points. WEE1 expression increased in carboplatin-treated OVCAR5 
cells, reaching a peak expression at 48 h, similar to HuR, whereas no increase in 
WEE1 was observed in carboplatin-treated OVCAR5-shHuR cells in which 
HuR expression was significantly inhibited (Figures 6A-D). WEE1 protein 
increased 1.3-fold in HuR-expressing OVCAR5-shCtrl cells upon carboplatin 
treatment (Figure 6B & C).  
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           We also determined the effect of HuR-regulated WEE1 expression on 
cell-cycle kinetics in the context of carboplatin treatment (Figures S4A & B). 
We observed that a higher percentage of cells accumulated in the G2/M phase in 
OVCAR5-shCtrl cells (29.5%) as compared to OVCAR5-shHuR (22.3%) 48 h 
after 7.5 µM carboplatin treatment (Figure S4B). Under normal culture 
conditions, the percentage of OVCAR5-shCtrl and OVCAR5-shHuR cells in the 
G2/M phase is similar (Figure S4B). In agreement with these in vitro 
observations, human ovarian tumor sections immunostained for HuR and WEE1 
revealed a positive correlation between cytoplasmic HuR expression and WEE1 
expression (p=0.048) (Figure 6E). These results offer a mechanism to explain 
why cytoplasmic localization of HuR is not predictive of a favorable outcome to 
gemcitabine treatment in our study when given as a combination therapy with 
carboplatin.  
            Since arrest of DNA replication by insertion of the gemcitabine analogue 
metabolite, triphosphate cytosine, is dependent on cell division, its effectiveness 
is likely to be compromised to some degree in cell cycle-arrested carboplatin-
treated cells even though dCK metabolizes gemcitabine as a consequence of 
elevated HuR cytoplasmic expression. Clinical experience clearly shows, 
however, that in ovarian cancer patients with platinum-sensitive relapse, 
progression-free survival is prolonged when gemcitabine is given in 
combination with carboplatin as compared to carboplatin monotherapy [243]. 
Evidence suggests that this synergy may result from the inhibition of repair of 
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platinum-induced DNA cross-links by gemcitabine [244, 245]. Our results 
suggest that patients with recurrent tumors be treated first with gemcitabine 
followed by treatment with carboplatin. To test directly the effect of WEE1-
mediated cell cycle arrest on gemcitabine efficacy, we measured survival of 
OVCAR5 cells grown in medium containing various concentrations of 
gemcitabine in the presence or absence of siWEE1. WEE1 inhibition increased 
the sensitivity of cells to gemcitabine 2-4 fold over the range of tested 
gemcitabine concentrations, and decreased the IC50 from 0.02 to 0.004 μM 
(Figure 18). This result suggests that it may also be advantageous to combine 
inhibition of WEE1 with gemcitabine and carboplatin as a combination second-
line therapy, thereby overcoming cell-cycle arrest and enhancing the therapeutic 
response to gemcitabine in patients with platinum-sensitive relapse. A small 
molecule WEE1 inhibitor, MK-1775, has been shown to enhance antitumor 
efficacy of p53-deficient tumor cells to DNA-damaging agents including 
cisplatin, carboplatin, gemcitabine and 5-fluorouracil [246-248], and a Phase II 
clinical trial (NCT02101775) testing MK-1775 in combination with gemcitabine 
to treat recurrent ovarian cancer is currently recruiting. Given our understanding 
of how gemcitabine affects tumor cell survival, addition of gemcitabine to this 
therapeutic strategy may have added benefit to all patients independent of p53 
status.   
              One limitation of our study is that HuR localization was analyzed in 
only one ovarian cancer subtype, serous ovarian tumors, a large majority of 
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which were high-grade tumors. While this subtype accounts for ~70% of ovarian 
tumors, these tumors differ from other tumor subtypes (endometrial, clear cell, 
mucinous) not only in morphology but also in gene expression profile, 
molecular genetic features, genetic and epidemiologic risk factors, precursor 
lesions, pattern of spread, and of particular relevance to this study, response to 
platinum-taxane based treatment [249, 250]. Indeed, expression of hENT1, dCK, 
5’NT, and RRM1 was found to be higher in undifferentiated and clear cell 
carcinoma as compared to serous ovarian tumors [251]. Given these substantial 
differences, the possibility that HuR localization might be an informative marker 
for gemcitabine response in other ovarian tumor subtypes warrants further study. 
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5.5 Figures and Tables 
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Figure 1. A. Treatment protocol for ovarian cancer patients with recurrent tumors. B. 
Ovarian tumor sections immunostained for HuR and representative of how staining 
intensity was scored. C. Kaplan-Meier plot of progression free survival (PFS) of patients 
with tumors having relatively low HuR cytoplasmic staining (scored -, +/-, or +) and 
tumors having high cytoplasmic HuR staining (scored ++ or +++).  
 
        
Figure 2. dCK silencing in ovarian cancer cells reduces gemcitabine response. Number 
of A2780, siCtrl-, and siHuR- transfected A2780 cells treated with gemcitabine at the 
indicated concentrations. * indicates p<0.005 
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Figure 3. Gemcitabine IC50 for OVCAR5, A2780, OVCA420, and OVCAR3 cells. 
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Figure 4. HuR nuclear to cytoplasmic translocation following treatment of OVCAR5 
cells with gemcitabine (GEM) associated with an increase in cytoplasmic dCK 
mRNA and protein. A. Western blot analysis for HuR and dCK in cytoplasmic and 
nuclear protein lysates. GAPDH provided loading control and allowed for 
quantitative comparison of HuR and dCK at different time points (values indicated 
beneath HuR and dCK panels). Lamin A/C provides marker for cytoplasmic extract 
purity. 
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Figure 5. HuR nuclear to cytoplasmic translocation following treatment of OVCAR5 
cells with gemcitabine (GEM) associated with an increase in cytoplasmic dCK mRNA 
and protein. A. qRT-PCR analysis of cytoplasmic dCK mRNA isolated from OVCAR5 
cells treated with GEM for different times. B. OVCAR5 cells grown in medium +/- GEM 
and immunostained for HuR. White arrows point to cytoplasmic HuR.  
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Figure 6. HuR translocation from the nucleus to the cytoplasm dCK expression 
following treatment of A2780 cells with gemcitabine for different times. A. Western 
blot analysis of HuR in cytoplasmic and nuclear protein lysates. Lamin A/C provides 
marker for cytoplasmic extract purity. B. Western blot analyses of dCK in whole cell 
protein lysates.  C. qRT-PCR analysis of cytoplasmic dCK mRNA isolated from 
A2780 cells treated with gemcitabine for different times. D. A2780 cells grown in 
medium +/- gemcitabine and immunostained for HuR. Arrows point to examples of 
cytoplasmic staining 
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Figure 7. HuR nuclear to cytoplasmic translocation following treatment of OVCAR5 
cells with gemcitabine (GEM) associated with an increase in cytoplasmic dCK mRNA 
and protein. Sections of human ovarian tumor, collected prior to drug treatment, were 
immunostained for HuR and dCK. Boxed area is enlarged in lower left corner of each 
panel in top row. 
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Figure 8. RNP-IP assays showing increased binding of dCK mRNA to HuR in response 
to gemcitabine. A. HuR protein-bound dCK (left) and SUMO-1 (right) mRNA amounts 
in A2780 cells grown in the presence or absence of 1μM GEM for 12 h as measured by 
qPCR. B. Left: Western blots of protein lysates prepared from A2780 cells grown in the 
presence or absence of 1  M GEM, before immunoprecipitation, and 
immunoprecipitates prepared with anti-HuR. Three separate IPs were assayed. Right: 
Western blots of protein lysates before immunoprecipitation, and immunoprecipitates 
prepared with IgG. 
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Figure 9. HuR response to gemcitabine regulates dCK expression. A. RNP-IP assays 
showing amount of HuR protein-bound dCK mRNA in the presence and absence of GEM 
as measured by qPCR. Two independent sets of cell lysates were assayed. B. Western 
blots of protein lysates prepared from OVCAR3 cells that were grown in the presence or 
absence of 1 mM GEM before immunoprecipitation (top). Western blot of 
immunoprecipitates prepared with IgG or anti-HuR is shown on the bottom. C. OVCAR3 
cells grown in medium +/- GEM and immunostained for HuR. Arrows point to examples 
of cytoplasmic staining. 
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Figure 10. HuR suppression inhibits increase in dCK expression in response to GEM. 
Western blot analysis of HuR and dCK protein expression in OVCAR5, OVCAR5-shCtrl, 
and OVCAR5-shHuR cells treated with or without 0.02 µM gemcitabine (GEM) for 
indicated times.  
 
 
 
OVCAR5 
No GEM 
    OVCAR5 
0.02 µM GEM 
0      24    72 
HuR 
GAPDH 
Hrs 
dCK 
0       6      12     24      48     72 
α-tubulin 
Hrs 
HuR (whole cell lysate) dCK (cytoplasmic) 
0       12       24     72  
HuR 
GAPDH 
Hrs 
dCK 
0       6      12     24      48     72 
α-tubulin 
Hrs 
HuR 
GAPDH 
0      24    72 Hrs 
    OVCAR5-shCtrl 
     0.02 µM GEM 
    OVCAR5-shHuR 
     0.02 µM GEM 
dCK 
α-tubulin 
Hrs 0       6      12     24     48     72   
dCK 
α-tubulin 
Hrs 0       6      12     24     48     72 
HuR 
GAPDH 
0      24    72 Hrs 
1.0     0.99    1.02    0.97    1.01    1.03 
1.0     1.05    1.35    1.59    1.59    1.65 
1.0     1.39    1.34    1.62    1.84    1.62 
1.0     1.13    1.14    1.03    1.04    1.15 
dCK/α-tubulin 
dCK/α-tubulin 
dCK/α-tubulin 
dCK/α-tubulin 
                                                                                                                                                                                              
 
 
134 
 
 
 
TCTTGCTGAAGACTACAGGCAGCCAAATGGTTCCAGATACTTCAGCTTTGTGTATCTTC
GTAACTTCATATTAATATAAGTTTCTTTAGAAAACCCAAGTTTTTAATCGTTTTTGTTTT
AAGGAAAAAAGATTTTTAAAATGAATCTTATGCAAAACTTTTTGACCAGTTTCTTTTCT
TTTGTTTTTTTTTTAAAAAAGACATTTAAAGACAAAGACATTATTTCTCATAGCAGGAA
ATGTAGAGGTAGATGGTTCCAGTATCAGCATAGTGACTAAACTACATTATAAAAGATC
CAGCTTCCTTCTGTCATTCCCCTCTTTTGTCTTCCTCAGCAGGTTGGCTTTTTTCCCTGG
TGCCTCTCACTTCGTTGGTGACCAGTTTCTTAAACTGAAAGCTTTAATGTTACATAGTA
AATGGTAGTGTGTCCTGTGTAAATTAGTGTACCTATTAAAAGTTGCAAAGTGGAATTA
AAGGAATCCCTAGAATAAGGATTCTGAAGTTTTATTTTAAATTATTATCTTCTTAACAG
TTTAGTCCCACCTCTTACTTCCTGCCTCAGTCTGCTTTCTCTACTGTCTGGATTAATTAG
GCAGCCTGCTATAAAGTTAAAGTCACACATTTCTATTTTGCAAACACTGTGATTACTCT
TTGCTTTGTAGTTTGCTTTGCTTTGTAGGGTTCTGCTTTTAAGTTTTTCTCTTTTTCAGA
CAAATTACTGATAAAAATGATATTGCTCTATATGTAATATATCCTGAAAGCATTATTTT
TTGTTGAATAGGAAATAAAATTAATGAAGACAGAGGCTAGAAAGCATCCATTAATTA
ATGAGACACACTTAACTACTTATCTCTAAACCATCTATGTGAATATTTGTAAAAATAAT
GAATGGACTCATCTTAGTTCTGTATATAAATATATTTTCTTTCTAGTTTGTTTAGTTAAG
GTGTGCAGTGTTTTTCCTGTGTATTAAACCTTTCCATTTTACGTTTTAGAAAATTTTATG
TATTTTAAAATAAGGGGAAGAGTCATTTTCACTTTTAAACTACTATTTTTCTTTCCAAGT
CATTTTTGTTTTTGGTTTCTTATTCAAAGATGATAATTTAGTGGATTAACCAGTCCAGA
CGCACTGATCTTTGCAAAGGAGACTTAATTTCAAATCTGTAATTACCATACATAAACTG
TCTCATTATACGTATGCATTTTTTTAGTTTGTTTTTGTTTGGTATAAATTAATTTGTTAAT
TAAATATTTCTTAAGTATAAACCTTATGAACTACAGTGGAGCTACACTCATTGAAATGT
AATTTCAGTTCTAAAAAGATGTAATAATCATTTTAGAATTAAAATTTATTCTACTTTTAA
ATAAATTATGAATATTAAAGGTGAAAATTGTATAAATTACTTTGATTCCATTTTAAGTG
GAGACATATTTCAGTGATTTTTAGTAACCTTTAAAAATGTATAATGACTTTTAAAATTT
GTAGAATTGAAAAGACGCTAATAAAAATTTATTATTTATTTGTCATGACTC 
 
Figure 11. DNA sequence of dCK 3’ untranslated region  
 
 
 
 
 
                                                                                                                                                                                              
 
 
135 
 
 
 
      A 
 
B 
 
 
Figure 12. A. Schematic of dual Luciferase reporter system. B. Ratio of Renilla 
and Fire fly Luciferase actives in gemcitabine treated cells were normalized to 
untreated cells. 
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Figure 13. HuR suppression reduces gemcitabine chemotherapeutic efficacy. A. Number 
of OVCAR5-shCtrl or OVCAR5-shHuR cells at 72 h following treatment with different 
concentrations of GEM. Western blot analysis of HuR of whole cell lysates in OVCAR5-
shCtrl or OVCAR5-shHuR cells. B. Numbers of OVCAR3-shHuRi699 cells treated with 
+/- 0.1μg/ml DOX and with different GEM concentrations. Western blot analysis of HuR 
in OVCAR3-shHuRi699 cultured in GEM-containing medium with or without DOX. 
shHuRi = inducible shHuR; shHuRc = constitutively expressed shHuR. *indicates p<0.05 
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Figure 14. Carboplatin IC50 for OVCAR5 cells. Cells were treated with various 
concentrations of carboplatin for 48 hr and 72 hr, after which the number of viable cells 
was determined.  
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Figure 15. Cytoplasmic HuR increase in response to carboplatin increases WEE1 
expression. A. Western blot analysis of HuR and WEE1 proteins in OVCAR5 cells 
treated with 7.5  M carboplatin for various times (0-72 h). Cytoplasmic and nuclear 
extracts were analyzed separately for HuR expression. GAPDH (a cytoplasmic marker) 
and Lamin A/C (a nuclear marker) analysis was also done to evaluate purity of 
cytoplasmic and nuclear extract preparations. B. WEE1 expression in OVCAR5 cells 
stably transfected with shHuR or with shCtrl (whole cell extracts). C. Cytoplasmic HuR 
and WEE1 expression in OVCAR5 cells treated with carboplatin for various times. 
Numbers in panels A and B indicate expression levels of HuR and WEE1 normalized to 
GAPDH. D.  
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Figure 16. Sections of human ovarian tumor, with high (left) and low (right) HuR and 
WEE1 expression collected prior to drug treatment, immunostained for HuR and WEE1. 
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Figure 17. HuR inhibition upon carboplatin treatment reduces accumulation of cells in 
G2/M phase. (A) Cell-cycle kinetics in OVCAR5-shCtrl and OVCAR5-shHuR cells 
treated with or without 7.5 µM carboplatin in the G/M phase. (B) Percentage of 
OVCAR5-shCtrl and OVCAR5-shHuR cells in the G2/M phase following treatment with 
or without 7.5 mM carboplatin. 
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Figure 18: WEE1 inhibition sensitizes OVCAR5 cells to gemcitabine. A. OVCAR5 
cells were transfected with siWEE1 or siCtrl for 6 h. Following addition of gemcitabine 
at various concentrations to the culture medium, cell viability was assayed after 72 h. B. 
Western blot of WEE1 in gemcitabine-treated OVCAR5 cells treated with siHuR or 
siCtrl. α-tubulin serves as a gel loading control. *indicates p<0.0001 
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Table 1.  Profile of patients in this study 
 
 
Age (yrs) 61.8 +/- 9.3* 
Race  Caucasian (29) 
African American (2) 
Stage Ib (1) 
Ic (1) 
II (1) 
IIb (1) 
IIc (1) 
IIIb (1) 
IIIc (24) 
unstaged (1) 
Grade g2  (4) 
g2-3 (3) 
g3 (24) 
Histology serous (27)  
serous/endometrioid (1) 
serous w/mucinous features (1) 
carcinosarcoma + serous (1) 
serous w/clear cell features (1) 
Optimal debulking 
 
20 optimal 
11 sub-optimal 
# first-line therapy carboplatin + paxlitaxel cycles  1.8 +/- 1.1* (range: 1-5) 
# second-line gemcitabine cycles  
(i.e., recurrent tumors) 
5.1 +/- 1.9* (range: 3-11) 
Second-line gemcitabine therapy  
combined with other chemo? 
Carboplatin (26) 
Carboplatin + avastin (1) 
Cisplatin (2) 
None (2) 
Progression Free Survival (mo) 8.5 +/- 4.8* (range: 3-26) 
 
*Mean +/- S.D. 
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Table 2. Correlation of cytoplasmic HuR status and tumor grade. (n = 30; one tumor in 
the study was ungraded. A correlation approached significance (p = 0.066) by Fisher’s 
exact test. 
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Chapter 6 
Summary and Future Directions 
 
6.1 Summary 
          The introduction of platinum based chemotherapy in 1977 extended the 
5-year overall survival rate for ovarian cancer patients from ~30% to ~40%, but 
this rate has remained the same over the past 40 years [250]. In current clinical 
practice, first-line standard-of-care treatment for all ovarian tumors, regardless 
of histosubtype, is a carboplatin/taxol combination drug therapy.  Given our 
current knowledge of the disperse epithelial origins of different ovarian tumor 
histosubtypes and the mutational diversity among the different types [22], it is 
not surprising that the success rate of treating ovarian cancer patients effectively 
is so dismal. The fact that ovarian tumors inevitably acquire drug resistance [252] 
adds to the difficulties faced in finding a better way to treat these patients.    
           Newly developed therapeutics targeting a single aberrantly expressed 
protein in one cancer-associated signaling pathway have made very little 
improvement on extension of patients’ survival [253]. The one-target approach 
focuses on a single gene whose overexpression is needed by the cancer cells for 
survival. The major limitation is that aberrantly expressed target genes are only 
involved in certain ovarian cancer histosubtypes suggesting the approach only 
works on that particular group of ovarian cancer.  That said, ~70% of ovarian 
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tumors are high-grade serous tumors [254], a subtype known to have high 
frequency mutations in a number of gene (e.g., TP53, CCNE1) [30]. It would be 
reasonable to think that targeting these genes would be an effective means to 
treat a majority of tumors. Yet, in practice, this is not the case.   It appears that 
cancer cells can activate compensatory pathways to overcome the inhibitory 
effect [255]. Although targeting multiple cancer-associated signaling pathways 
at once might achieve a better therapeutic outcome, the strategy has not yet been 
used well in developing a new therapeutic strategy. This is because that 
administration of several drugs targeting multiple signaling pathways is not 
clinically practical.  
         Ideally, in order to significantly improve ovarian cancer management, a 
potential target needs to be overexpressed across all ovarian tumor histosubtypes 
and play an important role in multiple molecular pathways. Here, we have 
demonstrated that highly elevated HuR is a potent regulator of post-
transcriptional gene regulation of many genes involved in multiple cancer-
associated signaling pathways in ovarian cancer cells. These findings suggest 
that inhibition of HuR protein expression might be an ideal strategy to improve 
ovarian cancer patient outcomes (i.e., delayed development of ascites and 
prolonged life span). Future studies of HuR-regulated genes in the different 
ovarian tumor histosubtypes are needed to support generalized use of HuR-
based therapy for all types.  
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         Furthermore, we discovered how cancer cells use HuR to regulate 
critical gene expression in response to chemodrugs to ensure survival advantage. 
Further understanding of HuR’s role in regulating cancer cells’ response to 
chemodrugs is likely to lead to a practical strategy to increase ovarian cancer 
cell chemosensitivity, thereby leading to a more enduring treatment. 
               HuR is a promising target in ovarian cancer therapy for the following 
reasons. First, HuR is ubiquitously expressed in many tissues, but generally 
overexpressed in tumors, including ovarian cancer [65, 66, 70]. HuR 
overexpression is across different histosubtypes of ovarian cancer. HuR 
overexpression is linked to the hyper-active PI3K-Akt- NFĸB pathway [88, 99] 
in which type I ovarian tumors often carry mutations (e.g. PTEN mutation and 
PIK3CA amplification) [30].  Although rarely having mutations in the PI3K-Akt 
pathway, type II ovarian tumors are characterized by extremely frequent p53 
mutations (over 80 % of cases) [30], especially in DNA binding domain (DBD) 
that can induce NFĸB expression [256] and most likely leads to enhanced HuR 
transcription. Second, silencing HuR causes wide-range inhibition of cancer-
associated signaling. Through analysis of cellular network interaction 
(ConsensusPathDB-human integrates interaction networks), HuR positively 
regulated genes are tightly associated with one another, mostly through protein-
protein interaction or gene regulatory interactions. Furthermore, HuR-regulated 
genes are involved in the core cancer-associated signaling pathways such as 
angiogenesis, apoptosis, cell proliferation, and invasion and metastasis 
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(The Database for Annotation, Visualization and Integrated Discovery). 
Therefore, development of a cancer therapy based upon HuR suppression is a 
highly rational approach for ovarian cancer. Third, HuR inhibition can delay 
onset of ascites development. More than one third of ovarian cancer patients 
have developed ascites upon diagnosis, and almost all patients present with 
ascites upon disease relapse [257]. Ascites is heavily associated with patient 
poor clinical outcome and correlates with the peritoneal spread of ovarian cancer 
[257]. Our in vivo data shows that HuR inhibition can lead to delayed onset of 
ascites formation. However, the mechanism underlying this observation requires 
further study. Ascites development is linked to increased leakiness of tumor 
microvasculature and obstruction of the lymphatic vessels [257]. HuR-regulated 
genes involved in angiogenesis and metastasis might play an important role in 
ascites development. Four, using siHuR therapy in combination with currently 
used drugs (carboplatin and taxols) is a promising strategy to improve drug 
efficacy and to overcome drug resistance. Our data suggests that HuR inhibition 
alone can significantly suppress ovarian cancer growth, largely due to hindering 
HuR’s direct regulation of numerous transcripts in multiple essential biological 
processes. In response to cancer-associated stressors, HuR rapidly regulates 
other transcripts indirectly to ensure cell survival [65, 66, 70]. HuR’s ability to 
modulate a number of genes to promote anti-apoptotic signaling (e.g., PIM1, 
Bcl-2, and Mcl-1) and to promote cell survival (e.g., p21 and WEE1) in 
response to cancer-associated stressors (e.g., chemotherapy and ionizing 
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irradiation) is strongly associated with drug resistance [70, 129, 130]. 
Gemcitabine in combined with carboplatin has been shown to reduce platinum-
based chemoresistance through a synergistic effect, in which gemcitabine 
incorporation changes DNA structure resulting in increased platinum-DNA 
adduct formation [258, 259]. However, stress-induced HuR-regulated WEE1 
overexpression can greatly reduce cell cycle dependence efficacy of gemcitabine. 
Therefore, combination of an HuR inhibitor, carboplatin, and gemcitabine is 
expected to be more effective in treating ovarian cancer. The chrysanthone-like 
compound MS-444 was identified using a high-throughput screen for small 
molecules that disrupt HuR mRNA interaction by Novartis Institutes for 
Biomedical Research [83]. MS-444 is a potent compound that binds to the 
RRM1 and RRM2 domain of HuR, preventing HuR’s homodimerization and its 
export from the nucleus [83]. Despite significant tumor inhibition and the 
selective sensitivity in cancer cells when used in the research setting [130], the 
lack of specificity (MS-444 is also an inhibitor of myosin light chain kinase) 
impacts the likelihood that MS-444 will ever be used in clinic [260, 261]. 
Development of a highly specific and superior HuR inhibitor is warrant. We 
have shown a great advantage using 3DNA dendrimer to deliver siHuR in vivo. 
Before siHuR becomes a practical strategy in the clinic, the FDA approved 
WEE1 inhibitor (MK1771) can be tested in combination with gemcitabine and 
carboplatin for a better efficacy in treating ovarian cancer.  
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              There are several limitations to our work presented here. All our in 
vitro results were generated using serous ovarian cancer cell lines. Other ovarian 
cancer histosubtypes have not been tested for the HuR inhibition strategy. Also, 
cancer cell lines have been grown in monolayer culture environment with large 
amounts of growth factors and high oxygen environment for many generations. 
It is likely that the cell culture setting cannot reflect the heterogeneity of primary 
tumors. Moreover, it is clear that none of the ovarian cancer histosubtypes 
originate from the ovarian epithelium [22, 30, 34]. The ovarian epithelium-
derived ID8 murine cancer model used in our studies might not accurately 
reflect ovarian cancer progression. Evaluating HuR expression and testing the 
HuR inhibition strategy in a fallopian tube epithelium-derived ovarian cancer 
mouse model [262] would further demonstrate the value of this therapeutic 
approach.  Despite these concerns, our findings, as well as those of other 
researchers investigating HuR’s role in promoting cancer cell survival and drug 
resistance in other tumor types, support further investigations to validate HuR-
targeted therapy as a promising new approach for the treatment of ovarian 
cancers.   
 
6.2 Future Directions 
6.2.1 Regulation of HuR in high-grade ovarian carcinoma 
             To date, increased levels of HuR are observed in high-grade ovarian 
tumors but little is known about how HuR is subjected to regulation. HuR’s role 
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in pro-proliferation and pro-survival has been well defined in many cancers 
including ovarian [70, 80, 263]. Moreover, high-grade ovarian tumors often 
develop resistance to chemotherapeutic drugs, and HuR has been shown to 
contribute to chemo-resistance [121]. HuR’s overexpression and abilities to 
promote tumor cell proliferation and survival against stressful stimuli implicate 
its role in promoting ovarian tumorigenesis. We demonstrated that targeted HuR 
inhibition can reduce ovarian tumor growth.  Unfortunately, the mechanisms 
that underlie overexpression of HuR in ovarian cancer remain unclear. HuR has 
been shown to be a transcriptional target of NFkB and a previous study of 
HuR’s regulation attributed its overexpression to the hyper active PI3K-Akt- 
NFkB pathway in gastric cancer cells and renal tubule cells [99] [88]. Given that 
mutations involved in activating the PI3K-Akt pathway are not often detected in 
high-grade ovarian tumors [30], the proposed mechanism of HuR regulation is 
not likely to apply to these tumors. Type I ovarian tumors, which include low-
grade serous, endometrioid, clear cells, and mucinous carcinomas, often have 
the aberrant PI3K-Akt pathway (e.g. PTEN mutation and PIK3CA amplification) 
[30].  In this class of ovarian tumors, HuR has low to moderate overexpression 
as compared to normal ovarian tissue [176]. Conversely, type II ovarian tumors 
are mostly composed of high-grade serous carcinoma which is the most 
aggressive ovarian malignancy, presenting in advanced stages upon diagnosis 
[22].  The molecular signature of type II tumors is characterized by extremely 
frequent p53 mutations (over 80 % of cases); however, unlike type I tumors, 
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these tumors rarely have mutations in the PI3K-Akt pathway [22]. Interestingly, 
high grade serous carcinomas often express HuR at very high levels compared to 
type I [176]. Therefore, it is important to examine the correlation between p53 
mutations and HuR overexpression. The A2780 ovarian cancer cell line has been 
shown to express a hyper-active PI3K-Akt pathway resulting from deletion of 
PTEN, while p53 status remains wild type [264-266].  In accordance with the 
published observation, our preliminary data showed that the high level of HuR 
in A2780 cells was reduced in a dose dependent manner with the treatment of 
the PI3K inhibitor LY294002 (Fig. 1). We will confirm the inhibition of HuR 
mRNA by performing qRT-PCR on A2780 cells treated with LY294002. 
            The p53 pathway is frequently found altered in most cancer cells of 
many tumor types, usually because of genetic mutations within the p53 sequence 
[267]. The missense mutations residing within the p53 DNA binding domain 
(DBD) cause an impaired binding of p53 to DNA and are the most common p53 
mutations [268]. According to the mechanism by which mutations affect the 
DBD folding, missense mutations on the DBD can be divided into two 
subgroups [268]. The first group is comprised of DNA-contact mutations (e.g. 
R248Q, R273H) which only disrupt amino acids interacting with DNA while the 
entire p53 structure remains unchanged [268]. In the second group, missense 
mutations alter the scaffold of the DNA-binding interface of p53 (e.g. R175H) 
[268]. These three mutations in the DBD (R248Q, R273H, and R175H) are the 
most frequently found p53 mutations in ovarian cancer [269]. They have been 
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shown to induce a unique expression profile by up-regulating ~100 genes, 
including those involved in cell growth, survival, adhesion, angiogenesis, and 
most interestingly, NFkB [268]. HuR mRNA has been shown to be a target of 
NFkB [88] Therefore, the p53, R248Q, R273H, and R175H mutations are very 
likely not only disable p53’s own growth suppressor function, but also increase 
HuR’s expression through the up-regulation of NFkB signaling.  Furthermore, 
HuR-stabilized mRNAs are involved in pathways that are similar to those up-
regulated by p53 mutants [70, 270]. This suggests that regulation of the gene 
signature induced by p53 mutants might be, at least in part, through or enhanced 
by HuR’s mRNA stabilizing function.  We aim to address how the RNA-binding 
protein HuR is regulated in ovarian cancer cells that express mutant p53 and to 
examine HuR’s influence on the cancer-related gene expression profile induced 
by mutant p53. Interestingly, not all high grade ovarian tumors express high 
level HuR [176]. It has been suggested that not all p53 mutants possess gain-of-
function activity in cancer-related signature genes [268]. This may provide an 
explanation HuR is expressed at low to normal levels in a small portion of high-
grade ovarian cancer. In future studies, we will evaluate patient high-grade 
ovarian tumor specimens from Lankenau Medical Center to determine if HuR 
level of expression correlates with the presence and absence of p53 mutations.  
 
6.2.2 HuR’s function in tumorigenesis and metastasis  
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We used the ID8-Fluc mouse model to demonstrate that targeted HuR 
inhibition can inhibit the growth of ovarian tumors. However, HuR’s role in 
tumorigenesis and tumor progression is not well understood. Whether HuR can 
promote tumorigenesis and/or metastasis still require further studies. A mouse 
model that can develop ovarian cancer with HuR overexpression will be a good 
tool to answer those questions. Recently, our lab has developed transgenic mice, 
Traffic+PDX1/Cre that overexpress HuR specifically in the pancreas (Fig. 2A). 
In pancreatic cells in culture, Traffic/HuR transfected cells express DsRed2 
fluorescent protein regulated by a constitutively active β-actin promoter (Fig. 
2B). Upon co-transfection of cells with the Traffic/HuR DNA construct and the 
PDX1/Cre DNA construct (promoter of the pancreatic and duodenal homeobox 
1 PDX-1 gene regulated Cre recombinase), the DsRed2-STOP cassette is 
excised between the two loxP sites by Cre recombinase-mediated recombination, 
and cells express the HuR/enhanced green fluorescent protein (eGFP) bicistronic 
transgene (Fig. 2B). Traffic/HuR mice expresses DsRed2 fluorescent protein 
with very low GFP fluorescent leak through, while the pancreas of PDX1/Cre 
mice does not fluoresce (Fig. 3). We bred the Traffic/HuR mice to PDX1/Cre 
mice to generate mice with HuR overexpression (and eGFP fluorescence) 
restricted to the pancreas. Traffic/HuR + PDX1/Cre double transgenic mice 
express high amounts of GFP in pancreas compared to the Traffic/HuR mice 
(Fig. 3). Western blot analysis of HuR in pancreas from double transgenic mice 
confirmed the HuR overexpression status as compared to wild type (WT) (Fig. 
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4). In order to study HuR’s function of tumorigenesis of ovarian cancer, we 
currently are breeding pTraffic/HuR mice to MISIIR/Cre mice, transgenic mice 
with Cre expression in ovaries. This mouse model can provide an ideal setting to 
manipulate HuR overexpression within ovaries for the study of HuR assisted 
tumor initiation within the context of an intact immune system and a more 
relevant tumor microenvironment. Furthermore, we are currently in the long-
term process of crossing pTraffic/HuR + MISIIR/Cre mice with MISIIR/TAg 
mice [271]. 100% of MISIIR/TAg transgenic female mice develop spontaneous 
bilateral epithelial ovarian tumor by 22 weeks of age [271]. Tumors can 
metastasize and invade the omentum, and form ascites (Fig. 5). By studying this 
triple transgenic mouse model, we aim to determine whether HuR 
overexpression can promote pathogenesis and facilitate ovarian tumor metastatic 
invasion. 
 
6.2.3 Evaluate ability of HuR inhibition to overcome drug resistance. 
              While ~80% of ovarian cancer patients receiving the standard 
therapeutic regimen have an initial favorable response, recurrent disease will 
occur in a majority of cases due to acquired drug resistance by the tumor cells 
[218]. The 5-year survival rate for these patients is only ~30% and is due to the 
fact that there are currently no effective therapies for advanced-stage ovarian 
cancer patients who initially have a favorable response to chemotherapy, but go 
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on to develop drug resistant-recurrent tumor cells [272]. These patients would 
clearly benefit from enhancing the efficacy of chemotherapy that already has 
some activity against these tumors and the development of novel, targeted 
approaches that effectively suppress tumor growth. There is a great clinical need 
to develop a new therapy that, when combined with current standard-of-care 
therapy, targets multiple drug resistance and oncogenic signaling transcripts and 
pathways. HuR is an ideal therapeutic target to overcome drug resistance and 
suppress ovarian tumor growth. In contrast to other approaches that have aimed 
to overcome drug resistance by targeting a single pathway/gene [e.g., WEE1 
inhibition in the setting of p53 deficiency] [273], selective inhibition of a post-
transcriptional regulatory RNA-binding protein, HuR, provides a unique 
opportunity to target multiple core signaling pathways that impact initial 
therapeutic efficacy, drug resistance, and oncogenic stimuli [61, 129-131]. To 
study whether targeting HuR expression should directly inhibit cancer cell 
viability and at the same time curtail cancer cell drug resistance mechanisms, we 
have developed ID8-luc (C+P)R cell lines that are resistant to high doses of 
carboplatin (C) and paclitaxel (P) (Fig. 6A).  
            We will test the ability of HuR inhibition by siHuR to sensitize tumor 
derived from ID8-luc (C+P)R cells to carboplatin and paclitaxel. Mice bearing 
ID8-luc (C+P)R-derived tumors will be treated with carboplatin and paclitaxel. 
Our expectation is that tumor cells in mice treated with siHuR will be sensitized 
to the drugs. As a consequence, tumor load in these mice, assessed by 
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bioluminescent imaging (BLI), will be significantly less than the tumor load in 
mice treated with siCTRL. We will also assay by RT-qPCR and immunoblots 
other proteins including WEE1, γ-GCS, TUBB3, HDAC1, DNMT1 for which 
there is some evidence supporting their involvement in drug resistance [129, 274, 
275]. Comparison of results of these analyses between siHuR and siCTRL mice 
will provide assessment of effectiveness of systemically-delivered siHuR and of 
FA targeting ability. Tumors from other mice, euthanized by cervical dislocation 
to preserve gene expression, will be processed for gene expression analysis. One 
pilot study showed that ovarian tumors derived from ID8-luc (C+P)R cells retain 
resistance to carboplatin (C) and paclitaxel (P) combined with siCtrl treatment 
(Fig. 6B). On the other hand, tumors became sensitizing to carboplatin (C) and 
paclitaxel (P) if mice were treated with siHuR (Fig. 6B). 
 
6.2.4 Identify HuR-regulated genes associated with drug resistance of ID8 
tumors.  
             To investigate the molecular mechanism underlying the development of 
drug resistance, we aim to identify and prioritize genes that correlate with the 
loss of drug resistance by comparing transcripts that are differentially expressed 
in tumors between siHuR- and siCTRL-treated mice. Five tumors from each 
treatment group will first be dissociated into single cells by gentle enzymatic 
digestion and physical means. Cell suspensions will be sorted for GFP 
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expression (GFP- cancer cells; GFP+ host stromal cells); note that ID8-luc cells 
also express GFP. This sorting will allow us to identify and distinguish 
differences in HuR-regulated gene expression in cancer cells and stromal cells 
that are the consequence of inhibiting HuR. We will prepare stromal and cancer 
cell extracts and use a HuR antibody to prepare ribonuclearprotein-
immunoprecipitates (RNP-IPs). The RNP-IPs will allow us to assess the 
interaction of HuR with specific mRNA cargos. We have performed RNP-IP 
analyses successfully to discover novel HuR target mRNAs upon DNA damage 
treatment ([85]; for review see Brody [237]) and to identify HuR-regulated 
genes in pancreatic and ovarian tumors following siHuR inhibition [98, 240]. 
Here, we will compare HuR-associated mRNAs from tumors of siHuR- and 
siCTRL-treated mice to identify novel HuR target mRNAs associated with drug 
resistance. The mRNAs will be identified by microarray analysis as described 
[85], in collaboration with the Thomas Jefferson University (TJU) Cancer 
Genomics Laboratory. In brief, biotinylated cDNA prepared from total RNA 
will be hybridized to Affymetrix GeneChip Human Transcriptome Array 2.0 
(HTA 2.0), allowing for interrogation of up to 285,000 full-length transcripts.  
 
6.2.5 HuR inhibition combats carboplatin and paclitaxel drug resistance in 
ascites-derived PDX tumors.  
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Malignant ascites presentation is detected in more than one third of 
ovarian cancer patients at diagnosis, and ascites development has been shown to 
be associated with chemoresistance and metastasis [257]. The onset and 
progression of ascites is less defined, but strongly associated with poor 
prognosis and patients’ life quality [257]. The fact that ascites plays an 
important role in the progression of the advanced-stage disease emphasizes the 
importance of understanding its pathophysiology and its impact on the biology 
of ovarian tumor cells, including its role in chemoresistance and mechanisms of 
tumor progression [257]. Ascites from ovarian cancer patients with recurrent 
tumors are readily available from standard palliative care procedures, and have 
been shown to be transplantable and generate PDX tumors [276-278].  We have 
successfully generated xenografts from ascites collected from mice injected with 
ID8-Fluc tumor cells (Fig. 7). We propose to generate PDX tumors from ascites 
derived from patients with recurrent ovarian tumors that have acquired drug 
resistance, thereby obviating the need to place cells in culture and generate drug 
resistant lines. We have elected to generate PDX lines directly from fresh ascites 
rather than use drug resistant lines generated by others for two reasons: 1) to 
retain histologic and genetic fidelity of ascites tumor cells before they are altered 
as a consequence of being maintained in culture, and 2) to have reliable and 
potentially important clinical data that corresponds to each ascites-derived PDX 
tumor.  
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Figure 1. A dose-dependent inhibition of HuR expression by LY294002 
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Figure 2. Traffic, the HuR inducible transgenic system. (A) Schematic illustration 
of Flag-tagged HuR pTraffic, transgenic system. (B) Fluorescence microscopy of 
A2780 cells transfected with Traffick/HuR-Flag with or without MISSIIR/Cre.  
SA: splice acceptor, pA: poly(A) signal, IRES: The internal ribosome entry site 
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Figure 3. Fluorescent microscopic analysis of pancreas from pDX1/Cre, 
pTraffic/HuR, and pTraffic/HuR&pDX1/Cre mice.  
 
 
 
Figure 4. Western blot analysis of HuR and Flag in pancreas from wild type 
(WT) and double transgenic mice (Traffic+ Cre) 
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Figure 5. MISIIR/Tag transgenic ovarian tumor mouse model. A. Ex-vivo 
image of a MISIIR/Tag mouse bearing bilateral ovarian tumors. B. 
Representative reconstructed CT scan of ovarian tumors of a MISIIR/Tag mouse. 
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Figure 6. Activated HuR is associated with drug resistance. (A) Sensitivity of 
ID8-luc parental cells (blue) and ID8-luc (C+P)R cells (red) to paclitaxel and 
carboplatin. (B) In vivo HuR inhibition sensitized resistant tumors to drugs. 
Mice bearing i.p. tumors derived from ID8-luc or ID8-luc (C+P)R cells were i.p. 
injected with C and P + siHuR or siCTRL and bioluminescent imaged (BLI) at 
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various times (A, B, C) according to the schedule shown at the top. Ratios ≥1 
indicate resistance; ratios <1 indicate sensitivity.  
 
 
 
 
Figure 7. Bioluminescent imaging of four C57BL/6J female mice bearing ID8-
Fluc ascites xenografts. 
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